{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":1459420,"items":[{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:14:48Z","timestamp":1757614488748,"version":"3.44.0"},"reference-count":85,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00043-6","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:47:33Z","timestamp":1666349253000},"page":"1237-1258","source":"Crossref","is-referenced-by-count":0,"title":["Venom allergy evaluation, diagnosis, and treatment"],"prefix":"10.1016","author":[{"given":"Amy","family":"Dowden","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","article-title":"Stinging insect hypersensitivity: a practice parameter update 2016","volume":"118","author":"Golden","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/ACI.0b013e32830638c5","article-title":"Epidemiology of insect-venom Anaphylaxis","volume":"8","author":"Bilo","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jama.1989.03430020082033","article-title":"Epidemiology of insect venom sensitivity","volume":"262","author":"Golden","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2500\/aap.2019.40.4250","article-title":"Stinging insect allergy and venom immunotherapy","volume":"40","author":"Ochfeld","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0091-6749(94)90351-4","article-title":"Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity","volume":"93","author":"Franklin","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0091-6749(85)90103-4","article-title":"Stinging insect allergy: national history and modification with venom immunotherapy","volume":"75","author":"Reisman","year":"1985","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ai.1994.v94.a54889","article-title":"Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis","volume":"94","author":"VanderLinden","year":"1994","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00043-6_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/ACI.0000000000000565","article-title":"Impact of climate change on insect-human interactions","volume":"19","author":"Vega","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib9","article-title":"Ants, wasps, and bees (Hymenoptera)","volume":"383","author":"Arke","year":"2002","journal-title":"Med Vet Entomol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/01.SMJ.0000097885.28467.21","article-title":"Allergic reactions to insect stings and bites","volume":"96","author":"Moffitt","year":"2003","journal-title":"South Med J"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.all.0000235905.87676.09","article-title":"Allergy to bumblebees","volume":"6","author":"DeGroot","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaci.2005.12.1313","article-title":"Clinical and entomological factors influence the outcome of sting challenge studies","volume":"117","author":"Golden","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib13","first-page":"247","article-title":"Hypersensitivity to the imported fire ant in Florida. Report of 104 cases","volume":"64","author":"Rhoades","year":"1977","journal-title":"J Fla Med Assoc"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2005.01.005","article-title":"Insect sting allergy and venom immunotherapy: a model and a mystery","volume":"115","author":"Golden","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jaip.2018.08.015","article-title":"Hymenoptera venom extracts in clinical practice","volume":"6","author":"Tracy","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2006.12.622","article-title":"Further fatalities caused by anaphylactic reactions to food. 2001\u20132006","volume":"119","author":"Bock","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib17","first-page":"123","article-title":"Fatal reactions to Hymenoptera stings","volume":"24","author":"Hoffman","year":"2003","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJM199208063270603","article-title":"Fatal and near-fatal reactions to food in children and adolescents","volume":"327","author":"Sampson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0091-6749(98)70190-3","article-title":"Epinephrine absorption in children with a history of anaphylaxis","volume":"101","author":"Simons","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mai.2001.119409","article-title":"Epinephrine absorption in adults; intramuscular vs subcutaneous injection","volume":"108","author":"Simons","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1067\/mai.2002.120758","article-title":"EpiPen Jr vs EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis","volume":"109","author":"Simons","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1067\/mai.2001.114706","article-title":"Insect allergy with negative venom tests","volume":"107","author":"Golden","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0091-6749(03)01537-9","article-title":"Negative venom skin test results in patients with histories of systemic reaction to a sting (Rostrum article)","volume":"112","author":"Golden","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1067\/mai.2001.115042","article-title":"Insect sting allergy: the dilemma of the negative skin test reactor","volume":"107","author":"Reisman","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0091-6749(85)90752-3","article-title":"Venom skin tests in insect-allergic and insect non-allergic populations","volume":"76","author":"Georgitis","year":"1985","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2015.10.007","article-title":"Venom allergy testing: is a graded approach necessary?","volume":"116","author":"Quirt","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/all.12123","article-title":"Simultaneous intradermal testing with Hymenoptera venoms is safe and more efficient than sequential testing","volume":"68","author":"Strohmeier","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib28","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0091-6749(96)70217-8","article-title":"Safety and efficacy of an accelerated method for venom skin testing","volume":"97","author":"Yocum","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/0091-6749(88)90085-1","article-title":"Allergens in Hymenoptera venom. XXI: cross reactivity and multiple reactivity between fire ant venom and bee and wasp venoms","volume":"82","author":"Hoffman","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.anai.2013.07.006","article-title":"Imported fire ant allergy: case presentation and review of incidence, prevalence, diagnosis and current treatment","volume":"111","author":"Steigelman","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJM199008163230707","article-title":"Reactions to the stings of the imported fire ant","volume":"323","author":"DeShazo","year":"1990","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1067\/mai.2000.105707","article-title":"Expanding habitat of the imported fire ant: a public health concern","volume":"105","author":"Kemp","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007611-197304000-00019","article-title":"Sensitivity to the imported fire ant: successful treatment with immunotherapy","volume":"66","author":"Triplett","year":"1973","journal-title":"South Med J"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0091-6749(93)90014-7","article-title":"Allergens in Hymenoptera venom, XXV: the amino acid sequence of Antigen 5 molecules: the structural basis of antigenic cross-reactivity","volume":"92","author":"Hoffman","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-6749(85)90040-5","article-title":"Antigenic cross-reactivity of venom proteins from hornets, wasps and yellow jackets","volume":"75","author":"King","year":"1985","journal-title":"J Allergy and Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0091-6749(82)80003-1","article-title":"Comparison of the allergenicity and antigenicity of yellow jacket and hornet venoms","volume":"69","author":"Reisman","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0091-6749(82)90064-1","article-title":"Comparison of the allergenicity and antigenicity of Polistes venom and other vespid venoms","volume":"70","author":"Reisman","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0091-6749(84)80015-9","article-title":"Studies of coexisting honey bee and vespid venom sensitivity","volume":"73","author":"Reisman","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib39","doi-asserted-by":"crossref","first-page":"090","DOI":"10.1016\/j.jaci.2013.09.047","article-title":"Identification of Hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens","volume":"133","author":"Cifuentes","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaci.2014.05.035","article-title":"Recombinant allergens rarely allow identification of Hymenoptera venom allergic patients with negative specific IgE to whole venom preparations","volume":"134","author":"Rafei-Shamsabadi","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00043-6_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/ACI.0000000000000574","article-title":"The role of component-resolved diagnosis in Hymenoptera venom allergy","volume":"19","author":"Bilo","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1365-2222.2009.03347.x","article-title":"Basophil responsiveness in patients with insect sting allergies and negative venom-specific immunoglobulin E and skin prick test results","volume":"39","author":"Korosec","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib43","first-page":"110","article-title":"Basophil activation can predict clinical sensitivity in patients after venom immunotherapy","volume":"20","author":"Kucera","year":"2010","journal-title":"J Investig Allergol Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1399-3038.2011.01233.x","article-title":"Monitoring honeybee venom immunotherapy in children with the basophil activation test","volume":"23","author":"Zitnik","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2009.03.017","article-title":"Venom immunotherapy reduces large local reactions to insect stings","volume":"123","author":"Golden","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaci.2008.03.031","article-title":"Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind placebo-controlled trial","volume":"122","author":"Severino","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib47","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jaip.2016.12.031","article-title":"Rush venom immunotherapy: ready for prime time?","volume":"5","author":"Golden","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib48","first-page":"801","article-title":"Rush venom immunotherapy in children","volume":"5","author":"Confino-Cohen","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S200917","article-title":"Clinical utility of rush venom immunotherapy","volume":"13","author":"Gurzelle","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000322258","article-title":"Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective","volume":"156","author":"Goldberg","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00043-6_bib51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaip.2017.02.005","article-title":"AAAAI\/ACAAI joint venom extract shortage task force report","volume":"5","author":"Golden","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2500\/aap.2007.28.3021","article-title":"Systemic reactions rates to field stings among imported fire ant sensitive patients receiving > 3 years of immunotherapy vs < 3 years of immunotherapy","volume":"28","author":"Forester","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0091-6749(00)90092-7","article-title":"Survey of patients after discontinuing venom immunotherapy","volume":"105","author":"Golden","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0091-6749(98)70167-8","article-title":"Long-term protection after stopping venom immunotherapy","volume":"101","author":"Lerch","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0091-6749(93)90060-S","article-title":"Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis","volume":"92","author":"Reisman","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0091-6749(91)90095-6","article-title":"Clinical and Immunologic follow-up of patients who stop venom immunotherapy","volume":"88","author":"Keating","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0091-6749(96)70302-0","article-title":"Discontinuing venom immunotherapy: outcome after five years","volume":"97","author":"Golden","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0091-6749(98)70239-8","article-title":"Discontinuing venom immunotherapy: extended observations","volume":"101","author":"Golden","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1081-1206(10)60425-5","article-title":"Long-term efficacy of venom immunotherapy","volume":"100","author":"Hafner","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0091-6749(91)90391-Z","article-title":"In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy","volume":"87","author":"Haugaard","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib61","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0091-6749(91)90392-2","article-title":"Honeybee venom allergy: results of a sting challenge 1 year after stopping venom immunotherapy in 86 patients","volume":"87","author":"Muller","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib62","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0091-6749(91)90378-2","article-title":"Venom immunotherapy: when is it reasonable to stop","volume":"87","author":"Reisman","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib63","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1034\/j.1398-9995.2000.00587.x","article-title":"Side effects of insect venom immunotherapy: results from an ECAACI strudy","volume":"55","author":"Mosbech","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2012.02.022","article-title":"Ultrarush vs semirush initiation of insect venom immunotherapy: a randomized controlled trial","volume":"130","author":"Brown","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib65","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.iac.2014.02.004","article-title":"Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients","volume":"34","author":"Niedoszytko","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib66","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2007.10.014","article-title":"Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis","volume":"121","author":"Bonadonna","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib68","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaci.2007.11.010","article-title":"Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis","volume":"121","author":"Gonzalez-de-Olano","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib69","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0091-6749(97)70135-0","article-title":"Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera therapy: a prospective, randomized, placebo-controlled trial","volume":"100","author":"Brockow","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib70","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","article-title":"Omalizumab mitigates anaphylaxis during ultra-rush honey bee venom immunotherapy in monoclonal mast cell activation syndrome","volume":"1","author":"daSilva","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib71","first-page":"225","article-title":"Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment with omalizumab","volume":"19","author":"Galera","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib72","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib73","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/cea.12582","article-title":"Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy","volume":"45","author":"Korosec","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM197807272990401","article-title":"A controlled trial of immunotherapy in insect hypersensitivity","volume":"299","author":"Hunt","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib75","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(03)12827-9","article-title":"Ant venom immunotherapy: a double blind placebo-controlled crossover trial","volume":"361","author":"Brown","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1398-9995.1979.tb02006.x","article-title":"Immunotherapy in bee sting hypersensitivity: bee venom vs whole body extract","volume":"34","author":"Muller","year":"1979","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib77","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1398-9995.2009.02198.x","article-title":"Bee venom immunotherapy \u2013 how early is it effective?","volume":"65","author":"Goldberg","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib78","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1067\/mai.2001.119154","article-title":"Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses","volume":"108","author":"Rueff","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib79","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1398-9995.2009.02118.x","article-title":"Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy","volume":"64","author":"Niedoszytko","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis \u2013 a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib81","series-title":"Monograph on insect allergy","first-page":"161","article-title":"Allergic reactions to biting insects","author":"Hoffman","year":"2003"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib82","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0091-6749(99)70348-9","article-title":"Skeeter syndrome","volume":"104","author":"Simons","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000053771","article-title":"Mosquito allergy: recombinant mosquito salivary antigens for new diagnostic tests","volume":"124","author":"Simons","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib84","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1081-1206(10)61262-8","article-title":"Evidence for natural desensitization to mosquito salivary allergens: mosquito saliva specific IgE and IgG levesl in children","volume":"93","author":"Peng","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00043-6_bib85","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3928\/19382359-20200214-01","article-title":"Infestations, bites, and insect repellents","volume":"49","author":"Kamath","year":"2020","journal-title":"Pediatr Ann"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:05:52Z","timestamp":1757055952000},"score":26.350704,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000436"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":85,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00043-6","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:15:03Z","timestamp":1757614503055,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00015-1","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:38:26Z","timestamp":1666348706000},"page":"419-439","source":"Crossref","is-referenced-by-count":0,"title":["Drug allergy testing"],"prefix":"10.1016","author":[{"given":"Min J.","family":"Lee","sequence":"first","affiliation":[]},{"given":"Jeffrey M.","family":"Chambliss","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2310\/7750.2013.12096","article-title":"Skin manifestations of outpatient adverse drug events in the united states: a national analysis","volume":"17","author":"Koelblinger","year":"2013","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaip.2018.06.010","article-title":"Drug-induced anaphylaxis documented in electronic health records","volume":"7","author":"Dhopeshwarkar","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaip.2013.01.006","article-title":"Treatment of patients with a history of penicillin allergy in a large tertiary-care academic hospital","volume":"1","author":"Picard","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice, Parameters","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib6","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","article-title":"Drug allergy","volume":"125","author":"Khan","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"10.1016\/B978-0-323-95061-9.00015-1_bib7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.1997.03550220101014","article-title":"Allergic reactions to drugs and biologic agents","volume":"278","author":"DeShazo","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/0003-4819-139-8-200310210-00012","article-title":"Delayed drug hypersensitivity reactions","volume":"139","author":"Pichler","year":"2003","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2018.19283","article-title":"Evaluation and management of penicillin allergy: a review","volume":"321","author":"Shenoy","year":"2019","journal-title":"J Am Med Assoc"},{"issue":"3 Suppl.","key":"10.1016\/B978-0-323-95061-9.00015-1_bib10","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jaci.2010.11.047","article-title":"Diagnosis and management of drug hypersensitivity reactions","volume":"127","author":"Romano","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaci.2011.08.042","article-title":"Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions","volume":"129","author":"Bircher","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2013.09.021","article-title":"Health care use and serious infection prevalence associated with penicillin \u201callergy\u201d in hospitalized patients: a cohort study","volume":"133","author":"Macy","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00015-1_bib14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/all.12881","article-title":"Drug allergies documented in electronic health records of a large healthcare system","volume":"71","author":"Zhou","year":"2016","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00015-1_bib15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999\u20132010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1742-7843.2006.pto_230.x","article-title":"The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population","volume":"98","author":"Borch","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaip.2017.02.012","article-title":"The effect of penicillin allergy testing on future health care utilization: a matched cohort study","volume":"5","author":"Macy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00015-1_bib18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0091-6749(99)70439-2","article-title":"Natural evolution of skin test sensitivity in patients allergic to \u03b2-lactam antibiotics","volume":"103","author":"Blanca","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0091-6749(81)90180-9","article-title":"Skin testing to detect penicillin allergy","volume":"68","author":"Sullivan","year":"1981","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00015-1_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/all.12142","article-title":"Skin test concentrations for systemically administered drugs \u2013 an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"68","author":"Brockow","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1081-1206(10)62624-5","article-title":"Systemic reactions to allergy skin tests","volume":"83","author":"Valyasevi","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3 Suppl. 3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib22","first-page":"S1","article-title":"Allergy diagnostic testing: an updated practice parameter","volume":"100","author":"Bernstein","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00015-1_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1081-1206(10)60123-8","article-title":"Suppression of histamine- and allergen-induced skin reactions: comparison of first- and second-generation antihistamines","volume":"102","author":"Dos Santos","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2222.1989.tb02338.x","article-title":"Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content","volume":"19","author":"Pipkorn","year":"1989","journal-title":"Clin Exp Allergy"},{"issue":"2 Suppl 1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib25","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1081-1206(10)60895-2","article-title":"Skin testing","volume":"96","author":"Oppenheimer","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"24","key":"10.1016\/B978-0-323-95061-9.00015-1_bib26","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMra1807761","article-title":"Penicillin allergy","volume":"381","author":"Castells","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaip.2017.07.033","article-title":"Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation?","volume":"6","author":"Macy","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaci.2014.07.062","article-title":"Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis","volume":"135","author":"Macy","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00015-1_bib29","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jaip.2019.06.001","article-title":"Cephalosporin allergy: current understanding and future challenges","volume":"7","author":"Khan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2014.10.011","article-title":"Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins","volume":"135","author":"Gaeta","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"9S","key":"10.1016\/B978-0-323-95061-9.00015-1_bib31","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaip.2020.08.002","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: general concepts","volume":"8","author":"Broyles","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00015-1_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11882-014-0459-z","article-title":"Evaluation of antibiotic allergy: the role of skin tests and drug challenges","volume":"14","author":"Solensky","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0091-6749(03)01783-4","article-title":"Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics","volume":"112","author":"Empedrad","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.aller.2010.06.008","article-title":"Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing","volume":"39","author":"Seitz","year":"2011","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00015-1_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2010.03.010","article-title":"Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy","volume":"104","author":"Mori","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00015-1_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.0105-1873.2005.00716.x","article-title":"Clindamycin skin testing has limited diagnostic potential","volume":"53","author":"Notman","year":"2005","journal-title":"Contact Dermat"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00015-1_bib37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaip.2016.10.021","article-title":"Current knowledge and management of hypersensitivity to aspirin and NSAIDs","volume":"5","author":"Laidlaw","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib39","series-title":"Basics of skin testing and drug challenges","first-page":"73","author":"Park","year":"2018"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib40","article-title":"Maintaining safety with SARS-CoV-2 vaccines","author":"Castells","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/all.12886","article-title":"In vitro tests for drug hypersensitivity reactions: an ENDA\/EAACI Drug Allergy Interest Group position paper","volume":"71","author":"Mayorga","year":"2016","journal-title":"Allergy"},{"issue":"17","key":"10.1016\/B978-0-323-95061-9.00015-1_bib43","doi-asserted-by":"crossref","first-page":"E532","DOI":"10.1503\/cmaj.171315","article-title":"Diagnosing and managing drug allergy","volume":"190","author":"Abrams","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: in vitro testing","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-7961-3-9","article-title":"The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives","volume":"3","author":"Boumiza","year":"2005","journal-title":"Clin Mol Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jaip.2019.08.032","article-title":"Fatal anaphylaxis due to graded drug challenge: a cautionary tale","volume":"8","author":"Solensky","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaip.2014.04.013","article-title":"Penicillin skin testing is a safe and effective tool for evaluating penicillin allergy in the pediatric population","volume":"2","author":"Fox","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00015-1_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamapediatrics.2016.0033","article-title":"Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children","volume":"170","author":"Mill","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.anai.2018.05.013","article-title":"Prospective assessment of diagnostic tests for pediatric penicillin allergy: from clinical history to challenge tests","volume":"121","author":"Ib\u00e1\u00f1ez","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jaip.2017.10.008","article-title":"Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test","volume":"6","author":"Tonson la Tour","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00015-1_bib51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1034\/j.1600-0536.2001.450502.x","article-title":"Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.0105-4538.2001.00001.x-i8","article-title":"General considerations for skin test procedures in the diagnosis of drug hypersensitivity","volume":"57","author":"Brockow","year":"2002","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00015-1_bib53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00015-1_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13601-017-0144-0","article-title":"Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America","volume":"7","author":"Torres","year":"2017","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00015-1_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/ACI.0b013e32833aa54d","article-title":"Patch testing in drug allergy","volume":"10","author":"Friedmann","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/jdv.13796","article-title":"Patch testing \u2013 a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics","volume":"31","author":"Pinho","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00015-1_bib57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1710-1492-4-2-66","article-title":"Patch testing in non-immediate drug eruptions","volume":"4","author":"Romano","year":"2008","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00015-1_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:08:18Z","timestamp":1757056098000},"score":25.74245,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000151"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":58,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00015-1","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:13:12Z","timestamp":1757614392877,"version":"3.44.0"},"reference-count":157,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00039-4","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:45:28Z","timestamp":1666349128000},"page":"1111-1145","source":"Crossref","is-referenced-by-count":1,"title":["New biologics in allergy"],"prefix":"10.1016","author":[{"given":"Heather K.","family":"Lehman","sequence":"first","affiliation":[]},{"given":"Colleen M.","family":"Sabella","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00039-4_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40265-013-0085-4","article-title":"Omalizumab: a review of its use in patients with severe persistent allergic asthma","volume":"73","author":"McKeage","year":"2013","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib5","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00039-4_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib12","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.anai.2019.08.077","article-title":"D450 Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind, placebo-controlled trials","volume":"123","author":"Gevaert","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib13","unstructured":"Genentech. FDA grants Breakthrough Therapy designation for Xolair (omalizumab) for food allergies. <https:\/\/www.gene.com\/media\/press-releases\/14740\/2018-08-12\/fda-grants-breakthrough-therapy-designat>; August 12, 2018."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib17","unstructured":"Identifier NCT03881696. Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH). National Library of Medicine: ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2005.09.030","article-title":"Treatment of recalcitrant atopic dermatitis with omalizumab","volume":"54","author":"Lane","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib19","first-page":"416","article-title":"Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema","volume":"21","author":"Ramirez del Pozo","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","article-title":"Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study","volume":"29","author":"Sheinkopf","year":"2008","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2005.12.045","article-title":"Efficacy of anti-IgE therapy in patients with atopic dermatitis","volume":"55","author":"Vigo","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib25","unstructured":"Xolair (omalizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2021."},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00039-4_bib28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"14","key":"10.1016\/B978-0-323-95061-9.00039-4_bib29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib30","unstructured":"Identifier NCT03580356. A phase III study of efficacy and safety of ligelizumab in the treatment of CSU in adolescents and adults inadequately controlled with H1-antihistamines. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib31","unstructured":"Identifier NCT03580369. A phase III study of efficacy and safety of ligelizumab in the treatment of CSU in adolescents and adults inadequately controlled with H1-antihistamines. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib32","unstructured":"Identifier NCT01552629. A study evaluating the safety and efficacy of QGE031 in atopic dermatitis patients. National Library of Medicine: ClinicalTrials.gov."},{"issue":"13","key":"10.1016\/B978-0-323-95061-9.00039-4_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/B978-0-323-95061-9.00039-4_bib34","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00039-4_bib35","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"20","key":"10.1016\/B978-0-323-95061-9.00039-4_bib36","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib37","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib38","unstructured":"Steinfeld J, Rofousse F, Kahn J-E, Gleich G, Rothenberg M, Wardlaw A, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. B93 Late Breaking ClTrials Airw Dis. p. A4212-A."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib39","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib40","unstructured":"Identifier NCT03085797. Effect of mepolizumab in severe bilateral nasal polyps. National Library of Medicine: ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib42","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib44","unstructured":"Identifier NCT03055195. Efficacy and safety study of mepolizumab in subjects with moderate to severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib45","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib46","doi-asserted-by":"crossref","first-page":"AB11","DOI":"10.1016\/j.jaci.2017.12.034","article-title":"Mepolizumab for treatment of asthma: post-approval academic practice experience","volume":"141","author":"Benjamin","year":"2018","journal-title":"J Allergy Clin Immunology"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib47","unstructured":"Nucala (mepolizumab) [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; 2019."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib51","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib52","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"10056","key":"10.1016\/B978-0-323-95061-9.00039-4_bib53","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/B978-0-323-95061-9.00039-4_bib54","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/B978-0-323-95061-9.00039-4_bib55","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib56","doi-asserted-by":"crossref","first-page":"AB249","DOI":"10.1016\/j.jaci.2019.12.106","article-title":"Clinical efficacy of benralizumab and its role in modifying mechanistic pathways in chronic idiopathic urticaria refractory to H1-antagonists","volume":"145","author":"Singh","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib57","unstructured":"Identifier NCT03401229. Efficacy and safety study of benralizumab for patients with severe nasal polyposis (OSTRO). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib58","unstructured":"Identifier NCT04053634. Efficacy and safety of benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with a history of frequent exacerbations (RESOLUTE). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib59","unstructured":"Identifier NCT04191304. A phase 3 study to evaluate the efficacy and safety of benralizumab in patients with hypereosinophilic syndrome (HES) (NATRON). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib60","unstructured":"Identifier NCT04157348. A study to evaluate if benralizumab compared to mepolizumab may be beneficial in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) (MANDARA). National Library of Medicine: ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"10.1016\/B978-0-323-95061-9.00039-4_bib62","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab vs placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","author":"Simpson","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10086","key":"10.1016\/B978-0-323-95061-9.00039-4_bib64","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib65","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10039","key":"10.1016\/B978-0-323-95061-9.00039-4_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/B978-0-323-95061-9.00039-4_bib67","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/B978-0-323-95061-9.00039-4_bib68","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/B978-0-323-95061-9.00039-4_bib69","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"10209","key":"10.1016\/B978-0-323-95061-9.00039-4_bib70","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib72","unstructured":"Identifier NCT03633617. Study to determine the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis (EoE). National Library of Medicine: ClinicalTrials.gov."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib73","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaip.2018.07.027","article-title":"Dupilumab for treatment of food allergy","volume":"7","author":"Rial","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib74","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib75","unstructured":"Identifier NCT04180488. Dupilumab for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine and who are na\u00efve to, intolerant of, or incomplete responders to omalizumab (CUPID). National Library of Medicine: ClinicalTrials.gov."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Thaci","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00039-4_bib78","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J Mol Biol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00039-4_bib80","first-page":"781","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet","volume":"4","author":"Hanania","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib81","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An Integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Investig Dermatology"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib83","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib84","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/jid.2010.361","article-title":"Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K\/Akt3 and PKC-delta in normal human dermal fibroblasts","volume":"131","author":"Moriya","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib85","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatology"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib86","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib87","unstructured":"Identifier NCT04146363. Evaluation of the efficacy and safety of lebrikizumab in moderate to severe atopic dermatitis (ADvocate1). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib88","unstructured":"Identifier NCT04178967. Evaluation of the efficacy and safety of lebrikizumab in moderate to severe atopic dermatitis (ADvocate2). National Library of Medicine: ClinicalTrials.gov."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib90","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S2213-2600(18)30201-7","article-title":"Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"6","author":"Russell","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00039-4_bib92","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib93","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib94","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib95","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib96","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib97","doi-asserted-by":"crossref","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib98","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ni.1852","article-title":"Sensing the outside world: TSLP regulates barrier immunity","volume":"11","author":"Ziegler","year":"2010","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunology"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib101","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/eji.201041195","article-title":"TSLP enhances the function of helper type 2 cells","volume":"41","author":"Kitajima","year":"2011","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00039-4_bib102","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/B978-0-323-95061-9.00039-4_bib103","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00039-4_bib104","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/B978-0-323-95061-9.00039-4_bib105","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib106","unstructured":"Identifier NCT03406078. Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). National Library of Medicine: ClinicalTrials.gov."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib107","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib108","unstructured":"Identifier NCT03809663. A dose ranging placebo-controlled double-blind study to evaluate the safety and efficacy of tezepelumab in atopic dermatitis. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib109","unstructured":"Identifier NCT04851964. Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib110","unstructured":"Identifier NCT04833855. Study to evaluate tezepelumab in adults with chronic spontaneous urticaria (INCEPTION). National Library of Medicine: ClinicalTrials.gov."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib111","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.193.2.255","article-title":"Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2","volume":"193","author":"Hirai","year":"2001","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/17476348.2015.992783","article-title":"The role of prostaglandins in allergic lung inflammation and asthma","volume":"9","author":"Claar","year":"2015","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib113","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00039-4_bib114","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib115","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib116","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib117","unstructured":"Identifier NCT02555683. Study of efficacy and safety of QAW039 in patients with severe asthma inadequately controlled with standard of care asthma treatment. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib118","unstructured":"Identifier NCT02563067. Study of efficacy and safety of QAW039 in patients with severe asthma inadequately controlled with standard of care asthma treatment. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib119","unstructured":"Identifier NCT03215758. Study of efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib120","unstructured":"Identifier NCT03226392. Study of efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib121","unstructured":"Identifier NCT03681093. Study of efficacy of fevipiprant in patients with nasal polyposis and asthma (THUNDER). National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib122","unstructured":"Identifier NCT03810183. A proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia. National Library of Medicine: ClinicalTrials.gov."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","article-title":"Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review","volume":"19","author":"Yang","year":"2018","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib124","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib126","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis","volume":"73","author":"Furue","year":"2018","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00039-4_bib127","doi-asserted-by":"crossref","first-page":"e0161877","DOI":"10.1371\/journal.pone.0161877","article-title":"IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib128","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib129","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00039-4_bib130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00039-4_bib131","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib132","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib133","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib134","unstructured":"Identifier NCT03989206. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib135","unstructured":"Identifier NCT03985943. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. National Library of Medicine: ClinicalTrials.gov."},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00039-4_bib136","doi-asserted-by":"crossref","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin\u2019?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib137","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/intimm\/dxn037","article-title":"Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system","volume":"20","author":"Kondo","year":"2008","journal-title":"Int Immunol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071665","article-title":"Interleukin-33: its emerging role in allergic diseases","volume":"23","author":"Ding","year":"2018","journal-title":"Molecules"},{"issue":"515","key":"10.1016\/B978-0-323-95061-9.00039-4_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib140","unstructured":"Identifier NCT03533751. A study investigating the efficacy, safety, and PK profile of ANB020 administered to adult subjects with moderate-to-severe AD (ATLAS). National Library of Medicine: ClinicalTrials.gov."},{"issue":"22","key":"10.1016\/B978-0-323-95061-9.00039-4_bib141","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib142","unstructured":"Identifier NCT03614923. Etokimab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP). National Library of Medicine: ClinicalTrials.gov."},{"issue":"5 Pt 1","key":"10.1016\/B978-0-323-95061-9.00039-4_bib143","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/ajrccm.159.5.9806008","article-title":"Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins","volume":"159","author":"Hoshino","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00039-4_bib144","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1067\/mai.2001.117929","article-title":"IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines","volume":"108","author":"Molet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib145","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1067\/mai.2003.1557","article-title":"Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression","volume":"111","author":"Chakir","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00039-4_bib146","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1067\/mai.2003.1414","article-title":"Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions","volume":"111","author":"Toda","year":"2003","journal-title":"J Allergy Clin Immunology"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00039-4_bib147","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Investig Dermatology"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00039-4_bib148","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib149","article-title":"Phase 2 randomized, double-blind study of IL-17-targeting with secukinumab in atopic dermatitis","author":"Ungar","year":"2020","journal-title":"J Allergy Clin Immunology"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib150","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00039-4_bib151","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.4049\/jimmunol.1600126","article-title":"Expression of IL-22 in the skin causes Th2-biased immunity, epidermal barrier dysfunction, and pruritus via stimulating epithelial Th2 cytokines and the GRP pathway","volume":"198","author":"Lou","year":"2017","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00039-4_bib152","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00039-4_bib153","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"10.1016\/B978-0-323-95061-9.00039-4_bib154","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib155","unstructured":"Dupixent (dupilumab) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2021."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib156","unstructured":"ICER. An assessment of biologics for severe asthma. Internet Document: November 29, 2018. <https:\/\/icer.org\/assessment\/asthma-2018\/>."},{"key":"10.1016\/B978-0-323-95061-9.00039-4_bib157","unstructured":"ICER. An assessment of crisaborole and dupilumab. Internet Document: May 25, 2017. <https:\/\/icer.org\/assessment\/atopic-dermatitis-2017\/>."}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:13:39Z","timestamp":1757056419000},"score":25.538052,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000394"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":157,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00039-4","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:23:51Z","timestamp":1775071431198,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier","isbn-type":[{"value":"9780323950619","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00011-4","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:37:30Z","timestamp":1666348650000},"page":"323-344","source":"Crossref","is-referenced-by-count":1,"title":["In vitro methods to assess allergy"],"prefix":"10.1016","author":[{"given":"Nicole","family":"Akar-Ghibril","sequence":"first","affiliation":[]},{"given":"Christopher","family":"Chang","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2004.06.046","article-title":"In vitro assays for the diagnosis of IgE-mediated disorders","volume":"114","author":"Hamilton","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Suppl 3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib2","first-page":"S1","article-title":"Allergy diagnostic testing: an updated practice parameter","volume":"100","author":"Bernstein","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2 Suppl","key":"10.1016\/B978-0-323-95061-9.00011-4_bib3","doi-asserted-by":"crossref","first-page":"S687","DOI":"10.1067\/mai.2003.123","article-title":"23. Clinical laboratory assessment of IgE-dependent hypersensitivity","volume":"111","author":"Hamilton","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00011-4_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1034\/j.1398-9995.2003.00227.x","article-title":"A further evaluation of the clinical use of specific IgE antibody testing in allergic diseases","volume":"58","author":"Soderstrom","year":"2003","journal-title":"Allergy"},{"issue":"7526","key":"10.1016\/B978-0-323-95061-9.00011-4_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(67)90615-0","article-title":"Diagnosis of allergy by an in-vitro test for allergen antibodies","volume":"2","author":"Wide","year":"1967","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib6","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.waojou.2019.100080","article-title":"IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper","volume":"13","author":"Ansotegui","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00011-4_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1515\/cclm-2014-0243","article-title":"The 3rd International Standard for serum IgE: international collaborative study to evaluate a candidate preparation","volume":"52","author":"Thorpe","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaci.2017.04.028","article-title":"ImmunoCAP cellulose displays cross-reactive carbohydrate determinant (CCD) epitopes and can cause false-positive test results in patients with high anti-CCD IgE antibody levels","volume":"141","author":"Hemmer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1398-9995.1990.tb01080.x","article-title":"Evaluation of a capsulated hydrophilic carrier polymer (the ImmunoCAP) for measurement of specific IgE antibodies","volume":"45","author":"Ewan","year":"1990","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00011-4_bib10","first-page":"448","article-title":"Recommendations for the use of in vitro methods to detect specific immunoglobulin E: are they comparable?","volume":"23","author":"Goikoetxea","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1081-1206(10)60618-7","article-title":"Accuracy of IgE antibody laboratory results","volume":"99","author":"Wood","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3343\/alm.2018.38.1.23","article-title":"Comparison of singleplex specific IgE detection immunoassays: ImmunoCAP Phadia 250 and Immulite 2000 3g allergy","volume":"38","author":"Park","year":"2018","journal-title":"Ann Lab Med"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib13","first-page":"329","article-title":"Comparison of three in vitro assays for serum IgE with skin testing in asthmatic children","volume":"73","author":"Kam","year":"1994","journal-title":"Ann Allergy"},{"issue":"6 Pt 1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1067\/mai.2000.105219","article-title":"Analytic precision and accuracy of commercial immunoassays for specific IgE: establishing a standard","volume":"105","author":"Williams","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.anai.2018.07.016","article-title":"Evaluation of the manufacturer-dependent differences in specific immunoglobulin E results for indoor allergens","volume":"121","author":"Wojtalewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00011-4_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jaip.2015.08.016","article-title":"Serological IgE analyses in the diagnostic algorithm for allergic disease","volume":"3","author":"Hamilton","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1096\/fj.01-0711fje","article-title":"Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment","volume":"16","author":"Hiller","year":"2002","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00011-4_bib18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1046\/j.1365-2222.2003.01784.x","article-title":"Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E","volume":"33","author":"Jahn-Schmid","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40629-015-0046-4","article-title":"Comparison of molecular and extract-based allergy diagnostics with multiplex and singleplex analysis","volume":"24","author":"Huss-Marp","year":"2015","journal-title":"Allergo J Int"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40413-018-0186-3","article-title":"Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis","volume":"11","author":"Heffler","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib21","doi-asserted-by":"crossref","first-page":"e35697","DOI":"10.1371\/journal.pone.0035697","article-title":"Allergen micro-bead array for IgE detection: a feasibility study using allergenic molecules tested on a flexible multiplex flow cytometric immunoassay","volume":"7","author":"Pomponi","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00011-4_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2222.2010.03470.x","article-title":"Cross-sectional survey on immunoglobulin E reactivity in 23,077 subjects using an allergenic molecule-based microarray detection system","volume":"40","author":"Scala","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00011-4_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/pai.12450","article-title":"Microarray-based IgE detection in tears of patients with vernal keratoconjunctivitis","volume":"26","author":"Leonardi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaci.2015.02.034","article-title":"Reduction in allergen-specific IgE binding as measured by microarray: a possible surrogate marker for effects of specific immunotherapy","volume":"136","author":"Wollmann","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00011-4_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2014.09.020","article-title":"A pitfall to avoid when using an allergen microarray: the incidental detection of IgE to unexpected allergens","volume":"3","author":"Incorvaia","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0091-6749(76)90033-6","article-title":"In vitro cross-allergenicity of major aeroallergenic pollens by the radioallergosorbent technique","volume":"57","author":"Bernstein","year":"1976","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaci.2006.05.012","article-title":"Apple allergy across Europe: how allergen sensitization profiles determine the clinical expression of allergies to plant foods","volume":"118","author":"Fernandez-Rivas","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/ACI.0b013e32814a5401","article-title":"Lipid transfer protein allergy: primary food allergy or pollen\/food syndrome in some cases","volume":"7","author":"Zuidmeer","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00011-4_bib29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.aller.2018.03.002","article-title":"How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children","volume":"46","author":"Del-Rio Camacho","year":"2018","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.05.043","article-title":"Tolerance to extensively heated milk in children with cow\u2019s milk allergy","author":"Nowak-Wegrzyn","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/j.1398-9995.2005.00705.x","article-title":"Humoral and cellular responses to cow milk proteins in patients with milk-induced IgE-mediated and non-IgE-mediated disorders","author":"Shek","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.200700414","article-title":"The panel of egg allergens, Gal d 1-Gal d 5: their improved purification and characterization","author":"Jacobsen","year":"2008","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2008.06.016","article-title":"Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy","author":"Ando","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2012.10.004","article-title":"Advances in diagnosing peanut allergy","author":"Sicherer","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.03.013","article-title":"Clinical reactivity to hazelnut may be better identified by component testing than traditional testing methods","author":"Kattan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.01.029","article-title":"Allergen recognition patterns in walnut allergy are age dependent and correlate with the severity of allergic reactions","author":"Ballmer-Weber","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2005.02.028","article-title":"Ana o 3, an important cashew nut (Anacardium occidentale L.) allergen of the 2S albumin family","author":"Robotham","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00011-4_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/00008480-200012000-00010","article-title":"Peanut and tree nut allergy","author":"Sicherer","year":"2000","journal-title":"Curr Opin Pediatr"},{"issue":"5 Pt 1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0091-6749(99)70419-7","article-title":"A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy","volume":"103","author":"Wood","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1034\/j.1399-3038.2003.00024.x","article-title":"Hay fever and predictive value of prick test and specific IgE antibodies: a prospective study in children","volume":"14","author":"Schafer","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"issue":"5 Pt 1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0091-6749(95)70255-5","article-title":"Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens","volume":"96","author":"Pastorello","year":"1995","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0091-6749(97)70133-7","article-title":"Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents","volume":"100","author":"Sampson","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00011-4_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1067\/mai.2001.114708","article-title":"Utility of food-specific IgE concentrations in predicting symptomatic food allergy","volume":"107","author":"Sampson","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000505728","article-title":"Specific IgE decision point cutoffs in children with IgE-mediated wheat allergy and a review of the literature","volume":"181","author":"Graham","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2332\/allergolint.09-OA-0096","article-title":"Usefulness of wheat and soybean specific IgE antibody titers for the diagnosis of food allergy","volume":"58","author":"Komata","year":"2009","journal-title":"Allergol Int"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00011-4_bib37","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1046\/j.1365-2222.2001.01175.x","article-title":"Validity of specific IgE antibodies in children with egg allergy","volume":"31","author":"Boyano Martinez","year":"2001","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1067\/mai.2001.111592","article-title":"Specific IgE levels in the diagnosis of immediate hypersensitivity to cows\u2019 milk protein in the infant","volume":"107","author":"Garcia-Ara","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1067\/mai.2003.1603","article-title":"Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship?","volume":"112","author":"Osterballe","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2222.2005.02150.x","article-title":"The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges","volume":"35","author":"Celik-Bilgili","year":"2005","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00011-4_bib41","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2007.01.038","article-title":"The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age","volume":"119","author":"Komata","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1067\/mai.2000.104941","article-title":"Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis","volume":"105","author":"Sicherer","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00011-4_bib43","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1067\/mai.2002.124775","article-title":"Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays","volume":"109","author":"Rance","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0091-6749(03)01537-9","article-title":"Negative venom skin test results in patients with histories of systemic reaction to a sting","volume":"112","author":"Golden","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1081-1206(10)61035-6","article-title":"Reproducibility of skin testing and serum venom specific IgE in Hymenoptera venom allergy","volume":"96","author":"Graif","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00011-4_bib46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1067\/mai.2001.114706","article-title":"Insect sting allergy with negative venom skin test responses","volume":"107","author":"Golden","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0091-6749(97)70222-7","article-title":"Timing of venom skin tests and IgE determinations after insect sting anaphylaxis","volume":"100","author":"Goldberg","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib48","first-page":"123","article-title":"Fatal reactions to hymenoptera stings","volume":"24","author":"Hoffman","year":"2003","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/cea.13090","article-title":"Component-resolved diagnostics to direct in venom immunotherapy: important steps towards precision medicine","volume":"48","author":"Blank","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib50","first-page":"368","article-title":"Comparison of in vivo and in vitro tests in the diagnosis of imported fire ant sting allergy","volume":"64","author":"Stafford","year":"1990","journal-title":"Ann Allergy"},{"issue":"5 Pt 1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0091-6749(99)70440-9","article-title":"Diagnostic performance of Food and Drug Administration-cleared serologic assays for natural rubber latex-specific IgE antibody. The Multi-Center Latex Skin Testing Study Task Force","volume":"103","author":"Hamilton","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"2 Suppl","key":"10.1016\/B978-0-323-95061-9.00011-4_bib52","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1067\/mai.2002.125334","article-title":"Clinical and laboratory-based methods in the diagnosis of natural rubber latex allergy","volume":"110","author":"Hamilton","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1398-9995.2006.01268.x","article-title":"Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate \u03b2-lactam allergy","volume":"62","author":"Fontaine","year":"2007","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0091-6749(93)90170-K","article-title":"Diagnostic tests in enzyme allergy","volume":"92","author":"Merget","year":"1993","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00011-4_bib55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0091-6749(98)70181-2","article-title":"Specific IgE to isocyanates: a useful diagnostic role in occupational asthma","volume":"101","author":"Tee","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"4 Pt 1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0091-6749(89)90364-3","article-title":"Specific serum antibodies against isocyanates: association with occupational asthma","volume":"84","author":"Cartier","year":"1989","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/meth.1997.0494","article-title":"Markers of mast cell degranulation","volume":"13","author":"Hogan","year":"1997","journal-title":"Methods"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00011-4_bib58","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI114051","article-title":"Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis","volume":"83","author":"Schwartz","year":"1989","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib59","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1398-9995.2010.02432.x","article-title":"Benefit of the basophil activation test in deciding when to reintroduce cow\u2019s milk in allergic children","volume":"66","author":"Rubio","year":"2011","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.anai.2015.01.006","article-title":"Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges","volume":"114","author":"Song","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib61","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1398-9995.2011.02754.x","article-title":"Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children","volume":"67","author":"Glaumann","year":"2012","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2012.06.003","article-title":"Basophil reactivity, wheal size, and immunoglobulin levels distinguish degrees of cow\u2019s milk tolerance","volume":"131","author":"Ford","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000440663","article-title":"In vitro diagnosis of immediate drug hypersensitivity: should we go with the flow","volume":"168","author":"Mangodt","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cyto.b.21084","article-title":"Basophilic histamine content and release during venom immunotherapy: insights by flow cytometry","volume":"84","author":"Nullens","year":"2013","journal-title":"Cytom B Clin Cytom"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00011-4_bib65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000049531","article-title":"Hymenoptera-venom-induced upregulation of the basophil activation marker ecto-nucleotide pyrophosphatase\/phosphodiesterase 3 in sensitized individuals","volume":"126","author":"Platz","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2222.2002.01305.x","article-title":"Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics","volume":"32","author":"Sanz","year":"2002","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00011-4_bib67","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.1365-2222.2004.02050.x","article-title":"The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome","volume":"34","author":"Gamboa","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/all.12952","article-title":"Systematic characterization of basophil anergy","volume":"72","author":"Puan","year":"2017","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0091-6749(97)70247-1","article-title":"Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine","volume":"100","author":"Zweiman","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Pt 2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib70","first-page":"665","article-title":"The relevance of anti-food antibodies for the diagnosis of food allergy","volume":"53","author":"Johansson","year":"1984","journal-title":"Ann Allergy"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00011-4_bib71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000318736","article-title":"Food-specific IgG4 lack diagnostic value in adult patients with chronic urticaria and other suspected allergy skin symptoms","volume":"155","author":"Antico","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.all.0000168792.27948.f9","article-title":"Food allergy diagnostics: scientific and unproven procedures","volume":"5","author":"Beyer","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00011-4_bib73","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1046\/j.1365-2222.1998.00367.x","article-title":"Unreliability of IgE\/IgG4 antibody testing as a diagnostic tool in food intolerance","volume":"28","author":"Jenkins","year":"1998","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00011-4_bib74","first-page":"150","article-title":"The leukocytic food allergy test: a study of its reliability and reproducibility. Effect of diet and sublingual food drops on this test","volume":"45","author":"Lehman","year":"1980","journal-title":"Ann Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00011-4_bib75","first-page":"86","article-title":"Unproven techniques in allergy diagnosis","volume":"15","author":"Wuthrich","year":"2005","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:16:47Z","timestamp":1757056607000},"score":25.22999,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000114"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":84,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00011-4","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:18:48Z","timestamp":1757625528916,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1989,12,1]],"date-time":"1989-12-01T00:00:00Z","timestamp":628473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1989,12,1]],"date-time":"1989-12-01T00:00:00Z","timestamp":628473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[1989,12]]},"DOI":"10.1016\/0091-6749(89)90156-5","type":"journal-article","created":{"date-parts":[[2004,11,16]],"date-time":"2004-11-16T14:05:01Z","timestamp":1100613901000},"page":"1073-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Chapter 16 Immunologic skin diseases"],"prefix":"10.1016","volume":"84","author":[{"given":"Diane E.","family":"Schuller","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/0091-6749(89)90156-5_BIB1","series-title":"Primer on allergic and immunologic diseases","first-page":"2910","article-title":"Vesiculobullous skin diseases with prominent immunologic features","volume":"258","author":"Millikan","year":"1987"},{"key":"10.1016\/0091-6749(89)90156-5_BIB2","series-title":"Primer on allergic and immunologic diseases","first-page":"2910","article-title":"Vesicobullous skin disease with prominent immunologic features","volume":"258","author":"Millikan","year":"1987"},{"key":"10.1016\/0091-6749(89)90156-5_BIB3","series-title":"Clinical immunology update, reviews for physicians","first-page":"317","article-title":"Hereditary angioneurotic edema","author":"Gigli","year":"1983"},{"key":"10.1016\/0091-6749(89)90156-5_BIB4","series-title":"Clinical immunology update, reviews for physicians","first-page":"317","article-title":"Hereditary angioneurotic edema","author":"Gigli","year":"1983"},{"key":"10.1016\/0091-6749(89)90156-5_BIB5","series-title":"Primer on allergic and immunologic diseases","first-page":"2900","article-title":"Allergic skin disorders","volume":"258","author":"Kaplan","year":"1987"}],"container-title":["Journal of Allergy and Clinical Immunology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0091674989901565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0091674989901565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:27:40Z","timestamp":1757442460000},"score":24.612528,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0091674989901565"}},"issued":{"date-parts":[[1989,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1989,12]]}},"alternative-id":["0091674989901565"],"URL":"https:\/\/doi.org\/10.1016\/0091-6749(89)90156-5","ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"published":{"date-parts":[[1989,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chapter 16 Immunologic skin diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/0091-6749(89)90156-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1989 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:14:35Z","timestamp":1757614475543,"version":"3.44.0"},"reference-count":117,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00037-0","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:44:36Z","timestamp":1666349076000},"page":"1039-1076","source":"Crossref","is-referenced-by-count":0,"title":["Oral, sublingual, and dermatologic immunotherapy for food allergy"],"prefix":"10.1016","author":[{"given":"Mary Grace","family":"Baker","sequence":"first","affiliation":[]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(00)67313-0","article-title":"A case of egg poisoning","volume":"171","author":"Schofield","year":"1908","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib2","first-page":"275","article-title":"Oral specific hyposensitization in the management of patients allergic to food","volume":"12","author":"Patriarca","year":"1984","journal-title":"Allergol Immunopathol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00037-0_bib3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s10620-005-2921-1","article-title":"New protocol for desensitization to wheat allergy in a single case","volume":"50","author":"Nucera","year":"2005","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-2036.2003.01468.x","article-title":"Oral desensitizing treatment in food allergy: clinical and immunological results","volume":"17","author":"Patriarca","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1081-1206(10)60026-9","article-title":"Successful oral desensitization for systemic peanut allergy","volume":"97","author":"Mansfield","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00037-0_bib6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2222.2012.04028.x","article-title":"Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children","volume":"42","author":"Thyagarajan","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2013.12.1037","article-title":"Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)","volume":"133","author":"Syed","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2012.10.048","article-title":"Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens","volume":"131","author":"Vickery","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib9","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2019.07.028","article-title":"Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy","volume":"144","author":"Patil","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/cea.13305","article-title":"Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness","volume":"49","author":"Orgel","year":"2019","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"10.1016\/B978-0-323-95061-9.00037-0_bib12","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Investigators PGoC","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00037-0_bib13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","article-title":"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"4","author":"Obh","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"10207","key":"10.1016\/B978-0-323-95061-9.00037-0_bib14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaci.2014.11.034","article-title":"Administration of a probiotic with peanut oral immunotherapy: a randomized trial","volume":"135","author":"Tang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","author":"Fleischer","year":"2019","journal-title":"JAMA."},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2010.12.1083","article-title":"Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization","volume":"127","author":"Kim","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2012.11.011","article-title":"Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial","volume":"131","author":"Fleischer","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jaci.2013.02.017","article-title":"Sublingual vs oral immunotherapy for peanut-allergic children: a retrospective comparison","volume":"132","author":"Chin","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaci.2014.11.005","article-title":"A randomized, double-blind, placebo-controlled pilot study of sublingual vs oral immunotherapy for the treatment of peanut allergy","volume":"135","author":"Narisety","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaci.2009.05.022","article-title":"Clinical efficacy and immune regulation with peanut oral immunotherapy","volume":"124","author":"Jones","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaci.2009.03.045","article-title":"Safety of a peanut oral immunotherapy protocol in children with peanut allergy","volume":"124","author":"Hofmann","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaci.2009.09.042","article-title":"Adverse reactions during peanut oral immunotherapy home dosing","volume":"124","author":"Varshney","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib25","article-title":"Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study","author":"Vickery","year":"2020","journal-title":"J Allergy Climmunol Pract"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2013.10.001","article-title":"Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions","volume":"2","author":"Wasserman","year":"2014","journal-title":"J Allergy ClImmunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.03.016","article-title":"Community private practice clinical experience with peanut oral immunotherapy","author":"Afinogenova","year":"2020","journal-title":"J Allergy ClImmunol Pract"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00037-0_bib28","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.jaip.2019.04.010","article-title":"First real-world safety analysis of preschool peanut oral immunotherapy","volume":"7","author":"Soller","year":"2019","journal-title":"J Allergy ClImmunol Pract"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10187","key":"10.1016\/B978-0-323-95061-9.00037-0_bib30","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib31","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2014.10.021","article-title":"Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992\u20132012","volume":"135","author":"Turner","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00037-0_bib32","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jaip.2019.04.025","article-title":"Epidemiology of anaphylaxis in critically ill children in the United States and Canada","volume":"7","author":"Ramsey","year":"2019","journal-title":"J Allergy ClImmunol Pract"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mai.2001.112031","article-title":"Fatalities due to anaphylactic reactions to foods","volume":"107","author":"Bock","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2006.12.622","article-title":"Further fatalities caused by anaphylactic reactions to food, 2001\u20132006","volume":"119","author":"Bock","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib35","first-page":"12","article-title":"Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy","volume":"39","author":"Morisset","year":"2007","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaci.2007.10.029","article-title":"Specific oral tolerance induction in children with very severe cow's milk-induced reactions","volume":"121","author":"Longo","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib37","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2008.09.030","article-title":"A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy","volume":"122","author":"Skripak","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.anai.2010.03.015","article-title":"Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study","volume":"105","author":"Pajno","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00037-0_bib39","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1365-2222.2011.03749.x","article-title":"Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy","volume":"41","author":"Martorell","year":"2011","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib40","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2011.10.023","article-title":"The safety and efficacy of sublingual and oral immunotherapy for milk allergy","volume":"129","author":"Keet","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaip.2015.01.017","article-title":"Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up","volume":"3","author":"Caminiti","year":"2015","journal-title":"J Allergy Climmunol Pract"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00037-0_bib45","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.12905","article-title":"Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children","volume":"71","author":"Giavi","year":"2016","journal-title":"Allergy."},{"issue":"3\u20134","key":"10.1016\/B978-0-323-95061-9.00037-0_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000454807","article-title":"Safety and efficacy of low-dose oral immunotherapy for hen's egg allergy in children","volume":"171","author":"Yanagida","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaip.2018.07.013","article-title":"Baked egg oral immunotherapy desensitizes baked egg allergic children to lightly cooked egg","volume":"7","author":"Bird","year":"2019","journal-title":"J Allergy Climmunol Pract"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000502956","article-title":"Effectiveness and safety of double-blind, placebo-controlled, low-dose oral immunotherapy with low allergen egg-containing cookies for severe hen's egg allergy: a single-center analysis","volume":"180","author":"Takaoka","year":"2019","journal-title":"Int Arch allergy immunology"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2006.09.016","article-title":"Egg oral immunotherapy in nonanaphylactic children with egg allergy","volume":"119","author":"Buchanan","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaci.2015.12.1316","article-title":"Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2008.09.007","article-title":"Immunologic changes in children with egg allergy ingesting extensively heated egg","volume":"122","author":"Lemon-Mul\u00e9","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaci.2012.06.006","article-title":"Dietary baked egg accelerates resolution of egg allergy in children","volume":"130","author":"Leonard","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaci.2008.05.032","article-title":"Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: hypothesis-generating observations","volume":"122","author":"Konstantinou","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib54","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/apa.14226","article-title":"Wheat oral immunotherapy was moderately successful but was associated with very frequent adverse events in children aged 6\u201318 years","volume":"107","author":"Kulmala","year":"2018","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaci.2018.08.041","article-title":"Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy","volume":"143","author":"Nowak-Wegrzyn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib56","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00037-0_bib57","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstr\u00f6m","year":"2019","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13223-017-0223-8","article-title":"Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab","volume":"13","author":"Andorf","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib61","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1034\/j.1398-9995.2001.056006498.x","article-title":"A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections","volume":"56","author":"Drachenberg","year":"2001","journal-title":"Allergy."},{"issue":"17","key":"10.1016\/B978-0-323-95061-9.00037-0_bib62","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1016\/j.vaccine.2010.02.009","article-title":"Lactic acid bacteria as adjuvants for sublingual allergy vaccines","volume":"28","author":"Van Overtvelt","year":"2010","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2352-4642(17)30041-X","article-title":"Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hsiao","year":"2017","journal-title":"Lancet Child Adolesc Health"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib64","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2016.11.010","article-title":"Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab","volume":"5","author":"Burk","year":"2017","journal-title":"J Allergy Climmunol Pract"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib65","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jaip.2017.09.016","article-title":"Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"6","author":"Bird","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.anai.2014.08.004","article-title":"Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis","volume":"113","author":"Lucendo","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/pai.12554","article-title":"Oral immunotherapy for peanut allergy induces eosinophilic esophagitis: three pediatric case reports","volume":"27","author":"Semancik","year":"2016","journal-title":"Pediatric Allergy Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib68","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2018.06.016","article-title":"Quality of life of food-allergic patients before, during, and after oral immunotherapy","volume":"7","author":"Epstein-Rigbi","year":"2019","journal-title":"J Allergy Climmunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib69","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/all.13330","article-title":"The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life","volume":"73","author":"Dunn Galvin","year":"2018","journal-title":"Allergy."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaip.2018.10.048","article-title":"Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy","volume":"7","author":"Blumchen","year":"2019","journal-title":"J Allergy ClImmunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.anai.2012.08.015","article-title":"Effect of oral immunotherapy to peanut on food-specific quality of life","volume":"109","author":"Factor","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00037-0_bib72","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/pai.13066","article-title":"Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial","volume":"30","author":"Reier-Nilsen","year":"2019","journal-title":"Pediatric Allergy Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/all.14350","article-title":"Quality of life of children aged 8\u201312 years undergoing food allergy oral immunotherapy: child and parent perspective","author":"Epstein-Rigbi","year":"2020","journal-title":"Allergy."},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2020.03.028","article-title":"Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy","author":"Blackman","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9925","key":"10.1016\/B978-0-323-95061-9.00037-0_bib75","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0140-6736(13)62301-6","article-title":"Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial","volume":"383","author":"Anagnostou","year":"2014","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2020.11.011","article-title":"Integrating oral immunotherapy into clinical practice","volume":"147","author":"Leonard","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.02.046","article-title":"An approach to the office-based practice of food oral immunotherapy","author":"Wasserman","year":"2021","journal-title":"J Allergy Climmunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib78","first-page":"1251","article-title":"Asthme d\u2019origine equine. Essai de desensibilisation par des cutireactions repetees","volume":"45","author":"Vallery-Radot","year":"1921","journal-title":"Bull Soc Med Hop Paris"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib79","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/pai.12869","article-title":"Safety and efficacy of epicutaneous immunotherapy for food allergy","volume":"29","author":"Wang","year":"2018","journal-title":"Pediatric Allergy Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaci.2017.11.003","article-title":"Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention and management","volume":"141","author":"Sicherer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee on Food Allergies: Global Burden, Causes, Treatment, Prevention, and Public Policy; Oria M.P., Stallings V.A., (eds.) Finding a path to safety in food allergy: assessment of the global burden, causes, prevention, management, and public policy. Washington, DC: National Academies Press (US); 2016.","key":"10.1016\/B978-0-323-95061-9.00037-0_bib81"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib82","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1172\/JCI115884","article-title":"Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice","volume":"90","author":"Wood","year":"1992","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2014.10.007","article-title":"Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy","volume":"135","author":"Brough","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib84","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2014.07.033","article-title":"Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence","volume":"134","author":"Venkataraman","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2045-7022-2-22","article-title":"Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice","volume":"2","author":"Mondoulet","year":"2012","journal-title":"Clin Transl allergy"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib86","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2222.2009.03430.x","article-title":"Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy","volume":"40","author":"Mondoulet","year":"2010","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib87","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2018.01951","article-title":"Antigen uptake by langerhans cells is required for the induction of regulatory T cells and the acquisition of tolerance during epicutaneous immunotherapy in OVA-sensitized mice","volume":"9","author":"Dioszeghy","year":"2018","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00037-0_bib88","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.4049\/jimmunol.1003134","article-title":"Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice","volume":"186","author":"Dioszeghy","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib89","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2016.03.057","article-title":"Epicutaneous immunotherapy induces gastrointestinal LAP(+) regulatory T cells and prevents food-induced anaphylaxis","volume":"139","author":"Tordesillas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00037-0_bib90","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/cmi.2016.14","article-title":"Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut","volume":"14","author":"Dioszeghy","year":"2017","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib91","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jaci.2016.01.008","article-title":"Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib92","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jaci.2016.08.017","article-title":"Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults","volume":"139","author":"Jones","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"10.1016\/B978-0-323-95061-9.00037-0_bib93","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/jama.2017.16591","article-title":"Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial","volume":"318","author":"Sampson","year":"2017","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib94","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2500\/aap.2020.41.200047","article-title":"An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial","volume":"41","author":"Fleischer","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib95","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.anai.2018.09.032","article-title":"Quantitative risk reduction through epicutaneous immunotherapy (EPIT): results from the PEPITES phase III trial","volume":"121","author":"Remington","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib96","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.anai.2020.11.015","article-title":"Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: relevance for exposure through restaurant meals","volume":"126","author":"Remington","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00037-0_bib97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2020.06.028","article-title":"Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results","volume":"146","author":"Fleischer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib98","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaip.2020.08.015","article-title":"Improvements in quality of life in children following epicutaneous immunotherapy (EPIT) for peanut allergy in the PEPITES and PEOPLE studies","volume":"9","author":"DunnGalvin","year":"2021","journal-title":"J Allergy Climmunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib99","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaci.2010.02.029","article-title":"Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity","volume":"125","author":"Dupont","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib100","doi-asserted-by":"crossref","first-page":"AB132","DOI":"10.1016\/j.jaci.2015.12.566","article-title":"Safety of Viaskin milk epicutaneous immunotherapy (EPIT) in IgE-mediated cow's milk allergy (CMA) in children (MILES study)","volume":"137","author":"Rutault","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib101","doi-asserted-by":"crossref","first-page":"e31967","DOI":"10.1371\/journal.pone.0031967","article-title":"Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice","volume":"7","author":"Mondoulet","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00037-0_bib102","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/cea.13037","article-title":"Treatment of gastric eosinophilia by epicutaneous immunotherapy in piglets sensitized to peanuts","volume":"47","author":"Mondoulet","year":"2017","journal-title":"Clin & Exp Allergy"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00037-0_bib103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cgh.2019.05.014","article-title":"Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis","volume":"18","author":"Spergel","year":"2020","journal-title":"Clin gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaip.2016.11.016","article-title":"Sublingual immunotherapy: historical perspective and practical guidance","volume":"5","author":"Cox","year":"2017","journal-title":"J Allergy ClImmunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jaci.2019.01.024","article-title":"Understanding differences in allergen immunotherapy products and practices in North America and Europe","volume":"143","author":"Mahler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00037-0_bib106","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11882-014-0473-1","article-title":"Immune mechanisms of sublingual immunotherapy","volume":"14","author":"Jay","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00037-0_bib107","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/039463200802100314","article-title":"Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy","volume":"21","author":"Marcucci","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib108","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2045-7022-2-2","article-title":"Mechanisms of allergen-specific immunotherapy","volume":"2","author":"Fujita","year":"2012","journal-title":"Clin Transl Allergy"},{"issue":"Suppl. 81","key":"10.1016\/B978-0-323-95061-9.00037-0_bib109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1398-9995.2006.01159.x","article-title":"Immunological mechanisms of sublingual immunotherapy","volume":"61","author":"Akdis","year":"2006","journal-title":"Allergy."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00037-0_bib111","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1398-9995.2006.01196.x","article-title":"Sublingual immunotherapy for cow's milk protein allergy: a preliminary report","volume":"61","author":"de Boissieu","year":"2006","journal-title":"Allergy."},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib112","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2005.08.027","article-title":"Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract","volume":"116","author":"Enrique","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib113","article-title":"Eosinophilic esophagitis during sublingual and oral allergen immunotherapy","author":"Cafone","year":"2019","journal-title":"Curr Opallergy Climmunology"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00037-0_bib114","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2018.06.018","article-title":"Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies","volume":"121","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib115","article-title":"Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy","volume":"7","author":"Blackman","year":"2019","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00037-0_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaip.2019.09.004","article-title":"The role of shared decision making in pediatric food allergy management","volume":"8","author":"Anagnostou","year":"2020","journal-title":"J Allergy ClImmunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00037-0_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2020.01.030","article-title":"Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies","author":"Greenhawt","year":"2020","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:12:58Z","timestamp":1757056378000},"score":24.553734,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000370"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":117,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00037-0","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:43:10Z","timestamp":1765888990367,"version":"3.44.0"},"reference-count":86,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00018-7","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:38:34Z","timestamp":1666348714000},"page":"511-541","source":"Crossref","is-referenced-by-count":1,"title":["Patch testing and the evaluation of contact allergy"],"prefix":"10.1016","author":[{"given":"Stephanie L.","family":"Mawhirt","sequence":"first","affiliation":[]},{"given":"Luz","family":"Fonacier","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology","volume":"55","author":"Bickers","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-5699(97)01186-9","article-title":"Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity","volume":"19","author":"Grabbe","year":"1998","journal-title":"Immunol Today"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00018-7_bib3","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/archderm.1991.01680090122016","article-title":"Recent developments in the pathogenesis of allergic contact dermatitis","volume":"127","author":"Kalish","year":"1991","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/1744666X.1.1.75","article-title":"Contribution of CD4(+) and CD8(+) T-cells in contact hypersensitivity and allergic contact dermatitis","volume":"1","author":"Vocanson","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.jid.5700174","article-title":"CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice","volume":"126","author":"Vocanson","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"3 Suppl","key":"10.1016\/B978-0-323-95061-9.00018-7_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2015.02.009","article-title":"Contact dermatitis: a practice parameter\u2014update 2015","volume":"3","author":"Fonacier","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaci.2012.06.048","article-title":"Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis","volume":"131","author":"Gittler","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jid.2019.03.1133","article-title":"Shifting paradigms in allergic contact dermatitis: the role of innate immunity","volume":"140","author":"Brys","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib9","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.3389\/fimmu.2018.02796","article-title":"Memory-like NK cells: remembering a previous activation by cytokines and NK cell receptors","volume":"9","author":"Pahl","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib10","doi-asserted-by":"crossref","first-page":"e0151031","DOI":"10.1371\/journal.pone.0151031","article-title":"NK cells respond to haptens by the activation of calcium permeable plasma membrane channels","volume":"11","author":"Grandcl\u00e9ment","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jaip.2020.02.009","article-title":"A hands-on approach to contact dermatitis and patch testing","volume":"8","author":"Schmidlin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00018-7_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-0536.2010.01702.x","article-title":"Validity of self-reported nickel allergy","volume":"62","author":"Josefson","year":"2010","journal-title":"Contact Dermat"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib14","series-title":"Contact dermatitis. Textbook of dermatology","first-page":"734","author":"Wilkinson","year":"1998"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/DER.0000000000000417","article-title":"North American Contact Dermatitis Group patch test results: 2015\u20132016","volume":"29","author":"DeKoven","year":"2018","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib16","first-page":"144","article-title":"Contact dermatitis II. Clinical aspects and diagnosis","volume":"9","author":"Krasteva","year":"1999","journal-title":"Eur J Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib17","unstructured":"Elder DE, Elenitsas R, Johnson BL Jr, et al., editors. Lever\u2019s histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2009."},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1046-199X(99)90058-1","article-title":"Facial dermatitis: patch test results and final diagnoses","volume":"10","author":"Katz","year":"1999","journal-title":"Am J Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.anai.2014.03.018","article-title":"Allergic contact dermatitis","volume":"113","author":"Fonacier","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01634989-200306000-00004","article-title":"Eyelid dermatitis: an evaluation of 447 patients","volume":"14","author":"Ayala","year":"2003","journal-title":"Am J Contact Dermat"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1365-2133.2008.08790.x","article-title":"Periorbital dermatitis \u2013 a recalcitrant disease: causes and differential diagnoses","volume":"159","author":"Feser","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2310\/6620.2007.06041","article-title":"Common contact allergens associated with eyelid dermatitis: data from the North American Contact Dermatitis Group 2003\u20132004 study period","volume":"18","author":"Rietschel","year":"2007","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/DER.0b013e31824a64ff","article-title":"p-tert-Butylphenol formaldehyde resin and its impact on children","volume":"23","author":"Herro","year":"2012","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/DER.0b013e31823d191f","article-title":"Recommendations for a screening series for allergic contact eyelid dermatitis","volume":"23","author":"Herro","year":"2012","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1468-3083.2008.02949.x","article-title":"Periocular dermatitis: a report of 401 patients","volume":"23","author":"Temesv\u00e1ri","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2310\/6620.2008.07046","article-title":"Patch-testing North American lip dermatitis patients: data from the North American Contact Dermatitis Group, 2001 to 2004","volume":"19","author":"Zug","year":"2008","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0536.2000.043006322.x","article-title":"Epidemiology of eczematous cheilitis at a tertiary dermatological referral centre in Singapore","volume":"43","author":"Lim","year":"2000","journal-title":"Contact Dermat"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1034\/j.1600-0536.2000.043004216.x","article-title":"Multicentre study of allergic contact cheilitis from toothpastes","volume":"43","author":"Francalanci","year":"2000","journal-title":"Contact Dermat"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2310\/6620.2010.09040","article-title":"Acute allergic contact dermatitis of the lips from peppermint oil in a lip balm","volume":"21","author":"Tran","year":"2010","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2009.09287.x","article-title":"Sites of dermatitis in a patch test population: hand dermatitis is associated with polysensitization","volume":"161","author":"Carlsen","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00018-7_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaip.2015.06.006","article-title":"Contact dermatitis for the practicing allergist","volume":"3","author":"Bernstein","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1525-1470.2008.00670.x","article-title":"Dispelling the myths behind pediatric patch testing-experience from our tertiary care patch testing centers","volume":"25","author":"Jacob","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/DER.0000000000000083","article-title":"Patch testing in children from 2005 to 2012: results from the North American contact dermatitis group","volume":"25","author":"Zug","year":"2014","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/pde.12873","article-title":"Contact sensitization in children: a retrospective study of 2,614 children from a single center","volume":"33","author":"Belloni Fortina","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1525-1470.2002.00057.x","article-title":"Nickel contact hypersensitivity in children","volume":"19","author":"Silverberg","year":"2002","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11882-014-0421-0","article-title":"Allergic contact dermatitis in children: review of the past decade","volume":"14","author":"Admani","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1470.2005.22100.x","article-title":"Contact sensitization in 1094 children undergoing patch testing over a 7-year period","volume":"22","author":"Seidenari","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2005.05014.x","article-title":"Hypersensitivity reactions in neonates and infants","volume":"18","author":"Carder","year":"2005","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11882-014-0444-6","article-title":"Invited commentary: recommendation for a North American pediatric patch test series","volume":"14","author":"Jacob","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaip.2014.05.004","article-title":"The role of contact dermatitis in patients with atopic dermatitis","volume":"2","author":"Aquino","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2133.2012.10852.x","article-title":"Contact sensitization to common haptens is associated with atopic dermatitis: new insight","volume":"166","author":"Thyssen","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0536.1999.tb06032.x","article-title":"Frequency of contact allergy in children with atopic dermatitis: results of a prospective study of 137 cases","volume":"40","author":"Giordano-Labadie","year":"1999","journal-title":"Contact Dermat"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib43","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/0378-6323.13992","article-title":"Allergic contact dermatitis in patients with atopic dermatitis: a clinical study","volume":"71","author":"Sharma","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00018-7_bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0536.2009.01537.x","article-title":"Contact hypersensitivity and allergic contact dermatitis among school children and teenagers with eczema","volume":"60","author":"Czarnobilska","year":"2009","journal-title":"Contact Dermat"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1600-0536.2007.01248.x","article-title":"Contact sensitization in atopic dermatitis: results of a prospective study of 89 cases in Tunisia","volume":"58","author":"Belhadjali","year":"2008","journal-title":"Contact Dermat"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2133.2001.04078.x","article-title":"Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis","volume":"144","author":"Mortz","year":"2001","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib47","first-page":"6","article-title":"Which children should we patch test?","volume":"32","author":"Beattie","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.clindermatol.2015.09.003","article-title":"Allergic contact dermatitis: kids are not just little people","volume":"33","author":"Brod","year":"2015","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0536.1984.tb00343.x","article-title":"The baboon syndrome: systemically-induced allergic contact dermatitis","volume":"10","author":"Andersen","year":"1984","journal-title":"Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12016-018-8686-z","article-title":"Systemic contact dermatitis","volume":"56","author":"Aquino","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4103\/0019-5154.110846","article-title":"Low nickel diet in dermatology","volume":"58","author":"Sharma","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"2-3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0048-9697(94)90403-0","article-title":"Quantitative aspects of nickel dermatitis. Sensitization and eliciting threshold concentrations","volume":"148","author":"Menn\u00e9","year":"1994","journal-title":"Sci Total Environ"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib53","first-page":"144","article-title":"Systemic contact-type dermatitis due to drugs","volume":"8","author":"Menn\u00e9","year":"1989","journal-title":"Semin Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00018-7_bib54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.0105-1873.2003.0225a.x","article-title":"Systemic contact dermatitis of the eyelids caused by formaldehyde derived from aspartame?","volume":"49","author":"Hill","year":"2003","journal-title":"Contact Dermat"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00018-7_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1600-0536.2012.02147.x","article-title":"Systemic allergic dermatitis presumably caused by formaldehyde derived from aspartame","volume":"67","author":"Veien","year":"2012","journal-title":"Contact Dermat"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib56","unstructured":"Fisher A. Fisher\u2019s contact dermatitis. 7th ed. (Rietschel R., Fowler J., editors); 2018."},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0001-7310(09)70057-2","article-title":"Dermatitis al\u00e9rgica de contacto por cosm\u00e9ticos [Allergic contact dermatitis to cosmetics]","volume":"100","author":"Laguna","year":"2009","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2001.114738","article-title":"Balsam-related systemic contact dermatitis","volume":"45","author":"Salam","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib59","first-page":"84","article-title":"Can oral challenge with balsam of Peru predict possible benefit from a low-balsam diet?","volume":"7","author":"Veien","year":"1996","journal-title":"Am J Contact Dermat"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib60","unstructured":"March 2014 | The Dermatologist\u00ae | Myroxylon Pereirae (balsam of Peru). <http:\/\/www.the-dermatologist.com>; [Accessed 19.06.20]."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.0105-1873.2005.00565.x","article-title":"Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix","volume":"52","author":"Frosch","year":"2005","journal-title":"Contact Dermat"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib62","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0105-1873.2005.00563.x","article-title":"Patch testing with a new fragrance mix \u2013 reactivity to the individual constituents and chemical detection in relevant cosmetic products","volume":"52","author":"Frosch","year":"2005","journal-title":"Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0536.2012.02169.x","article-title":"Patch testing with 2.0% (0.60 mg\/cm2) formaldehyde instead of 1.0% (0.30 mg\/cm2) detects significantly more contact allergy","volume":"68","author":"Pont\u00e9n","year":"2013","journal-title":"Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/DER.0000000000000075","article-title":"Formaldehyde","volume":"26","author":"Pont\u00e9n","year":"2015","journal-title":"Dermatitis"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0536.1999.tb06200.x","article-title":"An update of the risk assessment for methylchloroisothiazolinone\/methylisothiazolinone (MCI\/MI) with focus on rinse-off products","volume":"41","author":"Fewings","year":"1999","journal-title":"Contact Dermat"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/AC.2000.6344","article-title":"Methylchloro-isothiazolinone revisited","volume":"11","author":"Mowad","year":"2000","journal-title":"Am J Contact Dermat"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/DER.0b013e31827edc73","article-title":"Methylisothiazolinone","volume":"24","author":"Castanedo-Tardana","year":"2013","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2133.2008.08644.x","article-title":"para-Phenylenediamine: the profile of an important allergen. Results of the IVDK [published correction appears in Br J Dermatol. 2008 Sep;159(3):772]","volume":"159","author":"Schnuch","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib69","first-page":"E20","article-title":"para-Phenylenediamine","volume":"19","author":"Zapolanski","year":"2008","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib70","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2133.2005.06742.x","article-title":"Analysis of para-phenylenediamine allergic patients in relation to strength of patch test reaction","volume":"153","author":"Ho","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1440-0960.2004.00110.x","article-title":"Textile dye allergic contact dermatitis following paraphenylenediamine sensitization from a temporary tattoo","volume":"45","author":"Saunders","year":"2004","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib72","first-page":"332","article-title":"A 10-year review of p-phenylenediamine allergy and related para-amino compounds at the Ottawa Patch Test Clinic","volume":"22","author":"LaBerge","year":"2011","journal-title":"Dermatitis"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2310\/6620.2009.08081","article-title":"Positive patch test reactions to lanolin: cross-sectional data from the North American contact dermatitis group, 1994 to 2006","volume":"20","author":"Warshaw","year":"2009","journal-title":"Dermatitis"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00018-7_bib74","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamadermatol.2016.6136","article-title":"Pediatric contact dermatitis registry data on contact allergy in children with atopic dermatitis","volume":"153","author":"Jacob","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00018-7_bib75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2310\/6620.2008.08062","article-title":"Mixed dialkyl thioureas","volume":"20","author":"Anderson","year":"2009","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clindermatol.2010.11.007","article-title":"Effective prescribing in steroid allergy: controversies and cross-reactions","volume":"29","author":"Browne","year":"2011","journal-title":"Clin Dermatol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00018-7_bib77","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1398-9995.2009.02038.x","article-title":"Allergic hypersensitivity to topical and systemic corticosteroids: a review","volume":"64","author":"Baeck","year":"2009","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00018-7_bib78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2005.12.028","article-title":"Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity","volume":"54","author":"Jacob","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/DER.0000000000000261","article-title":"American Contact Dermatitis Society Core Allergen Series: 2017 Update","volume":"28","author":"Schalock","year":"2017","journal-title":"Dermatitis"},{"year":"2018","series-title":"Patch testing \u2013 test concentrations and vehicles for 4900 chemicals","author":"deGroot","key":"10.1016\/B978-0-323-95061-9.00018-7_bib80"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00018-7_bib81","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.anai.2018.03.003","article-title":"Contact dermatitis and patch testing for the allergist","volume":"120","author":"Fonacier","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib82","first-page":"59","article-title":"Excited skin syndrome: study of 39 patients","volume":"13","author":"Duarte","year":"2002","journal-title":"Am J Contact Dermat"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00018-7_bib83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/15569520802251130","article-title":"Quantitative relationships between patch test reactivity and use test reactivity: an overview","volume":"27","author":"Zaghi","year":"2008","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib84","unstructured":"American Contact Dermatitis Society (ACDS). Contact Allergy Management Program (CAMP). <http:\/\/www.contactderm.com>; [Accessed 19.06.20]."},{"key":"10.1016\/B978-0-323-95061-9.00018-7_bib85","unstructured":"Utilizing SkinSAFE (Formerly CARD \u2013 the Contact Allergen Replacement Database). Developed with Mayo Clinic. <http:\/\/www.allergyfreeskin.com>; [Accessed 19.06.20]."},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00018-7_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/DER.0000000000000346","article-title":"Positive patch test reaction in a patient taking dupilumab","volume":"29","author":"Puza","year":"2018","journal-title":"Dermatitis"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:09:07Z","timestamp":1757056147000},"score":24.534445,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000187"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":86,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00018-7","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T05:11:38Z","timestamp":1715490698493},"reference-count":141,"publisher":"Elsevier","isbn-type":[{"value":"9780323085939","type":"print"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2014]]},"DOI":"10.1016\/b978-0-323-08593-9.00063-2","type":"book-chapter","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T15:12:13Z","timestamp":1604502733000},"page":"1014-1031","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic Nonasthmatic Diseases of the Lung"],"prefix":"10.1016","author":[{"given":"Michael C.","family":"Sneller","sequence":"first","affiliation":[]},{"given":"Joseph R.","family":"Fontana","sequence":"additional","affiliation":[]},{"given":"James H.","family":"Shelhamer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib1","first-page":"455","article-title":"Grenzformen der periarteritis nodosa","volume":"42","author":"Klinger","year":"1931","journal-title":"Frankf Z Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib2","first-page":"202","article-title":"Uber generalisierte, septische efaberkrankungen","volume":"29","author":"Wegener","year":"1936","journal-title":"Verh Dtsch Pathol Ges"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib3","first-page":"533","article-title":"Wegener's granulomatosis: pathology and review of the literature","volume":"58","author":"Godman","year":"1954","journal-title":"Arch Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.30286","article-title":"Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis","volume":"63","author":"Falk","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9519","key":"10.1016\/B978-0-323-08593-9.00063-2_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/S0140-6736(06)68583-8","article-title":"Wegener's granulomatosis","volume":"367","author":"Woywodt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0889-857X(05)70232-5","article-title":"Epidemiology of the vasculitides","volume":"27","author":"Gonzalez-Gay","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib9","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6","article-title":"Epidemiology of Wegener's granulomatosis in northern Norway","volume":"43","author":"Koldingsnes","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0031-1279824","article-title":"Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Goodpasture syndrome: vasculitides with frequent lung involvement","volume":"32","author":"Gibelin","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"10.1016\/B978-0-323-08593-9.00063-2_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500921X","article-title":"Pathogenesis of Wegener's granulomatosis: current concepts","volume":"7","author":"Sarraf","year":"2005","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib12","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"Ludviksson","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I","article-title":"Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation","volume":"42","author":"Csernok","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib14","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/art.23557","article-title":"Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission","volume":"58","author":"Abdulahad","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-123-12-199512150-00005","article-title":"The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis","volume":"123","author":"Rao","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A","article-title":"Antineutrophil cytoplasmic antibodies","volume":"41","author":"Hoffman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib17","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.153.3.1271","article-title":"Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa","volume":"153","author":"Porges","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2249.1994.tb06579.x","article-title":"Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?","volume":"97","author":"Ballieux","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib20","first-page":"335","article-title":"Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells","volume":"141","author":"Savage","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.1780360312","article-title":"Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis","volume":"36","author":"Kerr","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib24","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.1780391020","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis","volume":"39","author":"Langford","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","article-title":"Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients","volume":"14","author":"Devaney","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3949\/ccjm.65.3.135","article-title":"The diagnostic utility of c-ANCA in Wegener's granulomatosis","volume":"65","author":"Langford","year":"1998","journal-title":"Cleve Clin J Med"},{"issue":"8980","key":"10.1016\/B978-0-323-08593-9.00063-2_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(95)91555-9","article-title":"A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis","volume":"346","author":"Rao","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000478-199104000-00001","article-title":"Surgical pathology of the lung in Wegener's granulomatosis: review of 87 open lung biopsies from 67 patients","volume":"15","author":"Travis","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib29","first-page":"423","article-title":"Renal biopsy pathology in Wegener's granulomatosis","volume":"74","author":"Horn","year":"1974","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"34","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener's granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib36","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib38","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib39","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R","article-title":"Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis","volume":"43","author":"Langford","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib42","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","article-title":"Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis","volume":"57","author":"Walsh","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib44","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides: proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib50","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.20928","article-title":"Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register","volume":"53","author":"Reinhold-Keller","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0b013e32834d85ce","article-title":"Churg-Strauss syndrome: update on pathophysiology and treatment","volume":"24","author":"Vaglio","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","article-title":"Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome","volume":"44","author":"Kiene","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9343(03)00359-0","article-title":"Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists","volume":"115","author":"Keogh","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib58","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0046-8177(83)80162-2","article-title":"Pulmonary angiitis and granulomatosis revisited","volume":"14","author":"Churg","year":"1983","journal-title":"Hum Pathol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib59","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"Hunninghake","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib9000","first-page":"543","article-title":"Multiple benign sarcoid of the skin","volume":"17","author":"Boeck","year":"1899","journal-title":"J Cutan Genitourin Dis"},{"issue":"9","key":"10.1016\/B978-0-323-08593-9.00063-2_bib9005","first-page":"887","article-title":"Sarcoidosis\u2014the beginning: historical highlights of personalities and their accomplishments during the early years","volume":"76","author":"Young","year":"1984","journal-title":"J Natl Med Assoc"},{"issue":"6","key":"10.1016\/B978-0-323-08593-9.00063-2_bib9010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM195102082440606","article-title":"Effect of cortisone in sarcoidosis","volume":"244","author":"Sones","year":"1951","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/B978-0-323-08593-9.00063-2_bib9015","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1378\/chest.67.5.532","article-title":"Transbronchial forceps lung biopsy through the fiberoptic bronchoscope. Diagnosis of diffuse pulmonary disease","volume":"67","author":"Joyner","year":"1975","journal-title":"Chest"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization","volume":"145","author":"Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib9020","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1164\/ajrccm.164.11.2106001","article-title":"Familial aggregation of sarcoidosis: a case\u2013control etiologic study of sarcoidosis (ACCESS)","volume":"164","author":"Rybicki","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1513\/pats.200607-138MS","article-title":"State of the art: lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis)","volume":"4","author":"Rossman","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib62","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/hmg\/ddq325","article-title":"Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups","volume":"19","author":"Sato","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib63","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1086\/378097","article-title":"HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites","volume":"73","author":"Rossman","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib64","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1164\/rccm.200512-1839OC","article-title":"Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis","volume":"174","author":"Hill","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1519","article-title":"Sarcoidosis is associated with a truncating splice site mutation in BTNL2","volume":"37","author":"Valentonyte","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib66","first-page":"1003","article-title":"Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis","volume":"49","author":"Hofmann","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib67","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib68","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1084\/jem.20040429","article-title":"Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis","volume":"201","author":"Song","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib69","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.4049\/jimmunol.181.12.8784","article-title":"T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jama.2011.10","article-title":"Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics","volume":"305","author":"Iannuzzi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib71","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1378\/chest.104.2.352","article-title":"Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis","volume":"104","author":"Winterbauer","year":"1993","journal-title":"Chest"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib72","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/thorax.56.6.487","article-title":"Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis","volume":"56","author":"Mollers","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1164\/ajrccm.165.2.2106084","article-title":"Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis","volume":"165","author":"Capelli","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/B978-0-323-08593-9.00063-2_bib9025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2249.2007.03423.x","article-title":"CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages","volume":"149","author":"Nishioka","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib74","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0002-9343(99)00223-5","article-title":"Lofgren's syndrome revisited: a study of 186 patients","volume":"107","author":"Mana","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000088688","article-title":"Overexpression of bcl-2 protein in bronchoalveolar lavage lymphocytes and macrophages in sarcoidosis","volume":"73","author":"Mermigkis","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib76","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm1097-1124","article-title":"Interleukin-15 protects from lethal apoptosis in vivo","volume":"3","author":"Bulfone-Paus","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib77","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/thorax.57.10.897","article-title":"Apoptosis resistant bronchoalveolar lavage (BAL) fluid lymphocytes in sarcoidosis","volume":"57","author":"Stridh","year":"2002","journal-title":"Thorax"},{"issue":"10 Pt 1","key":"10.1016\/B978-0-323-08593-9.00063-2_bib78","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib79","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0272-5231(05)70417-2","article-title":"Pulmonary sarcoidosis","volume":"18","author":"Lynch","year":"1997","journal-title":"Clin Chest Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib80","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1164\/arrd.1980.122.5.721","article-title":"Transbronchial lung biopsy in sarcoidosis: an approach to determine the optimal number of biopsies","volume":"122","author":"Gilman","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib81","first-page":"147","article-title":"Transbronchial needle aspiration improves the diagnostic yield of bronchoscopy in sarcoidosis","volume":"21","author":"Trisolini","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib82","series-title":"Non-neoplastic disorders of the lower respiratory tract. AFIP atlas of nontumor pathology, vol. 2. 123-36","author":"Travis","year":"2002"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib83","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib84","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/B978-0-323-08593-9.00063-2_bib85","article-title":"Corticosteroids for pulmonary sarcoidosis","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib86","first-page":"121","article-title":"Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"Park","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib87","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib88","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib89","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib90","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib91","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib92","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","author":"Muller-Quernheim","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib93","first-page":"87","article-title":"Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis","volume":"16","author":"Lewis","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib94","first-page":"107","article-title":"Azathioprine treatment of chronic pulmonary sarcoidosis","volume":"2","author":"Pacheco","year":"1985","journal-title":"Sarcoidosis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib95","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.1995.00540330053014","article-title":"Therapeutic considerations in patients with refractory neurosarcoidosis","volume":"52","author":"Agbogu","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib96","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000221005","article-title":"Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists","volume":"219","author":"Thielen","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaad.2005.02.023","article-title":"Ulcerative cutaneous sarcoidosis responding to adalimumab [abstract]","volume":"53","author":"Philips","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0037-9","article-title":"Treatment of therapy-resistant sarcoidosis with adalimumab","volume":"25","author":"Callejas-Rubio","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archderm.142.1.17","article-title":"Adalimumab for treatment of cutaneous sarcoidosis","volume":"142","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2133.2003.05042.x","article-title":"Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis","volume":"148","author":"Kouba","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00467-005-2086-3","article-title":"Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil","volume":"21","author":"Moudgil","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0041-3879(67)80033-3","article-title":"Chloroquine in the treatment of sarcoidosis: a report from the Research Committee of the British Tuberculosis Association","volume":"48","year":"1967","journal-title":"Tubercle"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib104","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch Neurol"},{"issue":"3 Pt 1","key":"10.1016\/B978-0-323-08593-9.00063-2_bib106","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib107","first-page":"558","article-title":"Skeletal sarcoidosis: successful treatment with hydroxychloroquine","volume":"2","author":"Shimoni","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/01676830.2010.524268","article-title":"Orbital sarcoidosis treated with hydroxychloroquine","volume":"30","author":"Rabinowitz","year":"2011","journal-title":"Orbit"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib109","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1164\/ajrccm.155.5.9154873","article-title":"Pentoxifylline in treatment of sarcoidosis","volume":"155","author":"Zabel","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imj.1958.7.2.132","article-title":"Goodpasture's syndrome (pulmonary hemorrhage associated with glomerulonephritis) [abstract]","volume":"7","author":"Stanton","year":"1958","journal-title":"Australas Ann Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib111","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.7326\/0003-4819-60-6-1009","article-title":"Immune aspects of the glomerulonephritis associated with pulmonary hemorrhage","volume":"60","author":"Scheer","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib112","doi-asserted-by":"crossref","first-page":"920","DOI":"10.7326\/0003-4819-62-5-920","article-title":"Pulmonary hemorrhage and glomerulonephritis","volume":"62","author":"Duncan","year":"1965","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib113","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ki.1978.72","article-title":"Goodpasture's syndrome: an analysis of 29 cases","volume":"13","author":"Teague","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib114","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(01)06077-9","article-title":"Goodpasture's disease","volume":"358","author":"Salama","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib116","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib117","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1999.055003926.x","article-title":"Goodpasture antigen: expression of the full-length \u03b13(IV) chain of collagen IV and localization of the epitopes exclusively to the noncollagenous domain","volume":"55","author":"Leinonen","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib118","doi-asserted-by":"crossref","first-page":"22737","DOI":"10.1074\/jbc.M803451200","article-title":"A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen","volume":"283","author":"Vancore","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib119","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa0910500","article-title":"Molecular architecture of the Goodpasture autoantigen in anti-GBM neprhitis","volume":"363","author":"Pedchenko","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/S0270-9295(03)00131-1","article-title":"Pathogenesis of Goodpasture syndrome: a molecular perspective","volume":"23","author":"Borza","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib121","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1046\/j.1523-1755.1999.00720.x","article-title":"The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity","volume":"56","author":"Phelps","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib122","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clim.2009.07.005","article-title":"The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease","volume":"133","author":"Yang","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib123","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1681\/ASN.V1291908","article-title":"In Goodpasture's disease, CD4+ T cells escape thymic deletion and are reactive with the autoantigen \u03b13(IV)NC1","volume":"12","author":"Salama","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaut.2008.04.005","article-title":"Advances in the pathogenesis of Goodpasture's disease: from Epitopes to antoantibodies to effector T cells","volume":"31","author":"Ooi","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib125","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulohephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib126","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MD.0b013e31822f6f68","article-title":"Anti-glomerular basement membrane disease","volume":"90","author":"Cui","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib127","series-title":"Non-neoplastic disorders of the lower respiratory tract","author":"Travis","year":"2002"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0272-6386(86)80151-2","article-title":"Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage","volume":"8","author":"Boyce","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archinte.1996.00440040118013","article-title":"The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition","volume":"156","author":"Niles","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/md.0b013e318067da56","article-title":"Alveolar hemorrhage in anti-basement membrane antibody disease","volume":"86","author":"Lazor","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib131","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/bmme.1996.0064","article-title":"Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis","volume":"59","author":"Litwin","year":"1996","journal-title":"Biochem Mol Med"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib132","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib133","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.1973.14","article-title":"Anti-glomerular basement membrane antibody-induced glomerulonephritis","volume":"3","author":"Wilson","year":"1973","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib134","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12016-010-8222-2","article-title":"Cutting edge issues in Goodpasture's disease","volume":"41","author":"Chan","year":"2011","journal-title":"Clin Rev Allerg Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00063-2_bib135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(96)90169-9","article-title":"Recurrent Goodpasture's disease","volume":"27","author":"Levy","year":"1996","journal-title":"Am J Kidney Dis"}],"container-title":["Middleton's Allergy"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323085939000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323085939000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:31:51Z","timestamp":1697023911000},"score":24.512676,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323085939000632"}},"issued":{"date-parts":[[2014]]},"ISBN":["9780323085939"],"references-count":141,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-08593-9.00063-2","published":{"date-parts":[[2014]]}},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T05:35:42Z","timestamp":1648877742364},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy &amp; Clinical Immunology International - Journal of the World Allergy Organization"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1027\/0838-1925.15.2.68","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T06:59:51Z","timestamp":1138690791000},"page":"068-072","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic Investigations in Neurological and Psychiatric Diseases"],"prefix":"10.1027","volume":"15","author":[{"given":"Krisztina","family":"Baraczka","sequence":"first","affiliation":[]}],"member":"101","container-title":["Allergy &amp; Clinical Immunology International - Journal of the World Allergy Organization"],"deposited":{"date-parts":[[2007,2,13]],"date-time":"2007-02-13T15:56:13Z","timestamp":1171382173000},"score":24.47176,"resource":{"primary":{"URL":"http:\/\/www.verlag-hanshuber.com\/zeitschriften\/doi.php?doi=10.1027\/0838-1925.15.2.68"}},"issued":{"date-parts":[[2003]]},"references-count":0,"journal-issue":{"issue":"02","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1027\/0838-1925.15.2.68","ISSN":["0838-1925"],"issn-type":[{"value":"0838-1925","type":"print"}],"published":{"date-parts":[[2003]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:19:20Z","timestamp":1757625560684,"version":"3.44.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1988,6,1]],"date-time":"1988-06-01T00:00:00Z","timestamp":581126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1988,6,1]],"date-time":"1988-06-01T00:00:00Z","timestamp":581126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[1988,6]]},"DOI":"10.1016\/0091-6749(88)90868-8","type":"journal-article","created":{"date-parts":[[2005,8,19]],"date-time":"2005-08-19T23:23:36Z","timestamp":1124493816000},"page":"1067-1077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunologic aspects of neurologic diseases"],"prefix":"10.1016","volume":"81","author":[{"given":"Burton","family":"Zweiman","sequence":"first","affiliation":[]},{"given":"Arnold I.","family":"Levinson","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/0091-6749(88)90868-8_BIB1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0166-2236(86)90077-9","article-title":"Cellular immune reactivity within the CNS","volume":"9","author":"Wekerle","year":"1986","journal-title":"Trends Neurol Res"},{"key":"10.1016\/0091-6749(88)90868-8_BIB2","first-page":"1","article-title":"Immunologically priviledged sites","volume":"25","author":"Barker","year":"1977","journal-title":"Adv Immunol"},{"volume":"60","year":"1959","author":"Burnet","key":"10.1016\/0091-6749(88)90868-8_BIB3"},{"key":"10.1016\/0091-6749(88)90868-8_BIB4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/295066a0","article-title":"A monoclonal antibody against human T suppressor or lymphocytes binds specifically to the surface of cultured oligodendrocytes","volume":"295","author":"Oger","year":"1982","journal-title":"Nature"},{"key":"10.1016\/0091-6749(88)90868-8_BIB5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0165-5728(86)90004-4","article-title":"Humoral immune responses within the human central nervous system following systemic immunization","volume":"11","author":"Sandberg-Wollheim","year":"1986","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0046-8177(83)80216-0","article-title":"Cell-mediated immunity in neurologic disease","volume":"17","author":"Zweiman","year":"1986","journal-title":"Hum Pathol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.410190611","article-title":"Lymphocyte phenotypes in the multiple sclerosis lesion\u2014what do they mean?","volume":"19","author":"Zweiman","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB8","first-page":"608","article-title":"Biology of disease\u2014analysis of autoimmune de-myelination: its impact upon multiple sclerosis","volume":"50","author":"Raine","year":"1984","journal-title":"Lab Invest"},{"key":"10.1016\/0091-6749(88)90868-8_BIB9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0165-5728(86)90014-7","article-title":"Monoclonal and polyclonal antibodies to myelin-basic protein determinants","volume":"10","author":"Day","year":"1986","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-5699(86)90072-1","article-title":"Genetic and molecular aspects of demyelination","volume":"7","author":"Gonatas","year":"1986","journal-title":"Immunol Today"},{"key":"10.1016\/0091-6749(88)90868-8_BIB11","series-title":"Immunoregulatory processes in MS and EAE","article-title":"Experimental autoimmune encephalomyelitis: pathogenesis and prevention","author":"Cohen","year":"1984"},{"key":"10.1016\/0091-6749(88)90868-8_BIB12","series-title":"Immunoregulatory processes in MS and EAE","article-title":"Cellular transfer of EAE","author":"Hinrichs","year":"1984"},{"key":"10.1016\/0091-6749(88)90868-8_BIB13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4049\/jimmunol.135.1.229","article-title":"Specificity of T lymphocyte lines for peptides of myelin basic protein","volume":"155","author":"Vandenbark","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB14","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.4049\/jimmunol.132.6.2690","article-title":"Recovery of myelin basic protein reactive lymphocytes from spinal cords of Lewis rats with autoimmune encephalomyelitis","volume":"132","author":"Burns","year":"1984","journal-title":"J Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.4049\/jimmunol.121.3.844","article-title":"Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat","volume":"120","author":"Stohl","year":"1978","journal-title":"J Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB16","first-page":"355","article-title":"Immunocytochemistry of myelin basic proteins in adult rats oligodendroglia","volume":"7","author":"Sternberger","year":"1985","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0008-8749(85)90047-4","article-title":"Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion","volume":"91","author":"Traugott","year":"1985","journal-title":"Cell Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.4049\/jimmunol.132.5.2402","article-title":"The immunopathology of experimental allergic encephalomyelitis. II. Endothelial cell Ia increased prior to inflammatory cell infiltration","volume":"132","author":"Sobel","year":"1984","journal-title":"J Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(85)80043-6","article-title":"On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation","volume":"8","author":"Traugott","year":"1985","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/317355a0","article-title":"T cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination","volume":"317","author":"Zamvil","year":"1985","journal-title":"Nature"},{"key":"10.1016\/0091-6749(88)90868-8_BIB21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4049\/jimmunol.136.5.1676","article-title":"Immunoregulation of passively induced allergic encephalomyelitis","volume":"136","author":"Willenberg","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-510X(75)90138-0","article-title":"The onset and progression of the lesion in multiple sclerosis","volume":"25","author":"Adams","year":"1975","journal-title":"J Neurol Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB23","first-page":"71","article-title":"Characterization and distribution of lymphocytes subpopulations in multiple sclerosis plaques versus autoimmune demyelination lesions","volume":"8","author":"Traugott","year":"1985"},{"key":"10.1016\/0091-6749(88)90868-8_BIB24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1056\/NEJM198701083160202","article-title":"Selective loss of the suppressor-inducer T cell subset in progressive multiple sclerosis","volume":"316","author":"Morimoto","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/0091-6749(88)90868-8_BIB25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0090-1229(81)90072-6","article-title":"Lymphocyte adherence in multiple sclerosis: role of monocytes and increased sensitivity of MS lymphocytes to prostaglandin E","volume":"19","author":"Dore-Duffy","year":"1981","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-5728(83)90037-1","volume":"4","author":"Merrill","year":"1983","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0161-4630(81)90153-1","article-title":"Adherence of human peripheral blood lymphocyte to virus infected cells: role of the cytoskeleton and prostaglandin E","volume":"6","author":"Dore-Duffy","year":"1981","journal-title":"Prostaglandins Med"},{"key":"10.1016\/0091-6749(88)90868-8_BIB28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0022-510X(81)90019-8","article-title":"Hyperreactivity to myelin basic protein in MS","volume":"52","author":"Eggers","year":"1981","journal-title":"J Neurol Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB29","first-page":"263","article-title":"Cellular and humoral immune responses in human cerebrospinal fluid","author":"Brooks","year":"1983"},{"key":"10.1016\/0091-6749(88)90868-8_BIB30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.33.10.1305","article-title":"Analysis of B cell activation in cerebrospinal fluid lymphocytes in multiple sclerosis","volume":"33","author":"Levinson","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/0091-6749(88)90868-8_BIB31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/WNL.26.7.693","article-title":"Immunologic characterization of cerebrospinal fluid lymphocytes","volume":"26","author":"Levinson","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/0091-6749(88)90868-8_BIB32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJM197710202971602","article-title":"In vitro cell-mediated immunity of cerebrospinal lymphocytes to myelin basic protein in primary demyelinating diseases","volume":"297","author":"Lisak","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/0091-6749(88)90868-8_BIB33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-510X(83)90218-6","article-title":"Mitogen and antigen stimulation of multiple sclerosis cerebrospinal fluid lymphocytes in vitro","volume":"58","author":"Reunanen","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM198009253031301","article-title":"Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis","volume":"303","author":"Noronha","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/0091-6749(88)90868-8_BIB35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0008-8749(84)90113-8","article-title":"Generation of phenotypic helper\/inducer and suppressor\/cytotoxic T cell lines from cerebrospinal fluid in multiple sclerosis","volume":"84","author":"Clark","year":"1984","journal-title":"Cell Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1172\/JCI111541","article-title":"Spinal fluid lymphocytes responsive to autologous and allogeneic cells in multiple sclerosis and control individuals","volume":"74","author":"Birnbaum","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/0091-6749(88)90868-8_BIB37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-5728(83)90037-1","volume":"4","author":"Merrill","year":"1983","journal-title":"J Neuroimmunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1984.tb14813.x","article-title":"Clinical trials in multiple sclerosis: problems and opportunities","volume":"436","author":"Silberberg","year":"1984","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1749-6632.1984.tb14808.x","article-title":"The use of cyclo-phosphamide in the treatment of multiple sclerosis","volume":"436","author":"Weiner","year":"1984","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1749-6632.1984.tb14810.x","article-title":"Plasmapharesis and combined immunosuppressive drug therapy in chronic progressive multiple sclerosis","volume":"436","author":"Khatri","year":"1984","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1749-6632.1984.tb14807.x","article-title":"Clinical trials of Copolymer I in multiple sclerosis","volume":"436","author":"Bornstein","year":"1984","journal-title":"An NY Acad Sci"},{"key":"10.1016\/0091-6749(88)90868-8_BIB42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3171\/jns.1984.61.2.0207","article-title":"Viral infections of the nervous system","volume":"61","author":"Weiner","year":"1984","journal-title":"J Neurosurg"},{"key":"10.1016\/0091-6749(88)90868-8_BIB43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0167-5699(86)90025-3","article-title":"Immune-mediated injury of virus-infected oligodendrocytes","volume":"7","author":"Rodriquez","year":"1986","journal-title":"Immunol Today"},{"key":"10.1016\/0091-6749(88)90868-8_BIB44","first-page":"16L680","article-title":"The role of myelin P2 protein in the production of experimental allergic neuritis","author":"Rostami","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0008-8749(85)90233-3","article-title":"Transfer of experimental allergic neuritis with P2-reactive T cell lines","volume":"91","author":"Rostami","year":"1985","journal-title":"Cell Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp.44.7.565","article-title":"Immune responses in experimental allergic neuritis","volume":"44","author":"Hughes","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/0091-6749(88)90868-8_BIB47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/272639a0","article-title":"Transfer of demyelination with experimental allergic neuritis serum by intra-neural injection","volume":"272","author":"Saida","year":"1978","journal-title":"Nature"},{"key":"10.1016\/0091-6749(88)90868-8_BIB48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.410090703","article-title":"Diagnostic considerations in Guillain-Barr\u00e9 syndrome","volume":"9","author":"Asbury","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ana.410090719","article-title":"Chronic relapsing in (dysimmune) in polyneuropathy: pathogenesis and treatment","volume":"9","author":"Dalakas","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB50","series-title":"Peripheral neuropathy","first-page":"2050","article-title":"Acute inflammatory demyelinating neuropathies","author":"Arnason","year":"1984"},{"key":"10.1016\/0091-6749(88)90868-8_BIB51","first-page":"235","article-title":"Immunology of Guillain-Barre syndrome","volume":"8","author":"Steiner","year":"1985"},{"key":"10.1016\/0091-6749(88)90868-8_BIB52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1212\/WNL.33.2.234","article-title":"Immune reactions to P2 protein in human inflammatory neuropathies","volume":"33","author":"Zweiman","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/0091-6749(88)90868-8_BIB53","first-page":"1","article-title":"Cell-mediated demyelination of peripheral nerve in tissue culture","volume":"21","author":"Arnason","year":"1969","journal-title":"Lab Invest"},{"key":"10.1016\/0091-6749(88)90868-8_BIB54","first-page":"905","article-title":"Anti-peripheral nerve myelin antibody in patients with demyelinating neuropathy","volume":"82","author":"Koski","year":"1985"},{"key":"10.1016\/0091-6749(88)90868-8_BIB55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ana.410110112","article-title":"In vivo demyelinating activity of sera from patients with Guillain-Barr\u00e9 syndrome","volume":"11","author":"Saida","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB56","first-page":"A106","article-title":"Demyelinative conduction block produced by intraneural injection of human Guillain-Barr\u00e9 serum into rat sciatic nerve","volume":"32","author":"Sumner","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/0091-6749(88)90868-8_BIB57","first-page":"362","article-title":"Studies on the humoral mechanisms of inflammatory demyelinating neuropathies","volume":"30","author":"Tandon","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/0091-6749(88)90868-8_BIB58","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1986.03380100107031","article-title":"NIH Consensus Development Statement. The utility of therapeutic plasmapharesis for neurological disorders","volume":"256","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/0091-6749(88)90868-8_BIB59","first-page":"633","article-title":"Immunological findings in sensory carcinomatous neuropathy","volume":"6","author":"Zeromski","year":"1970","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/0091-6749(88)90868-8_BIB60","first-page":"1225","article-title":"IgM in human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associate glycoprotein","volume":"81","author":"Ilyas","year":"1984"}],"container-title":["Journal of Allergy and Clinical Immunology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0091674988908688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0091674988908688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:44:15Z","timestamp":1757443455000},"score":24.298775,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0091674988908688"}},"issued":{"date-parts":[[1988,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1988,6]]}},"alternative-id":["0091674988908688"],"URL":"https:\/\/doi.org\/10.1016\/0091-6749(88)90868-8","ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"published":{"date-parts":[[1988,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunologic aspects of neurologic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/0091-6749(88)90868-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1988 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:27:54Z","timestamp":1758796074762,"version":"3.44.0"},"reference-count":0,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1971,1,1]],"date-time":"1971-01-01T00:00:00Z","timestamp":31536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1971,1,1]],"date-time":"1971-01-01T00:00:00Z","timestamp":31536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[1971,1]]},"DOI":"10.1016\/s0091-6749(71)80328-7","type":"journal-article","created":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T11:35:18Z","timestamp":1190201718000},"page":"B5-B6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro lymphocyte response of patients with immunologic deficiency diseases"],"prefix":"10.1016","volume":"47","member":"78","container-title":["Journal of Allergy and Clinical Immunology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674971803287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674971803287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:46:24Z","timestamp":1758793584000},"score":24.267591,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674971803287"}},"issued":{"date-parts":[[1971,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1971,1]]}},"alternative-id":["S0091674971803287"],"URL":"https:\/\/doi.org\/10.1016\/s0091-6749(71)80328-7","ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"published":{"date-parts":[[1971,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro lymphocyte response of patients with immunologic deficiency diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0091-6749(71)80328-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1971 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:44:40Z","timestamp":1761093880016,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.anai.2018.01.032","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T02:38:05Z","timestamp":1517798285000},"page":"350-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biologics in allergic and immunologic diseases"],"prefix":"10.1016","volume":"120","author":[{"given":"Mauli","family":"Desai","sequence":"first","affiliation":[]},{"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.01.032_bib0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1081-1206(10)61707-3","article-title":"Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma","volume":"92","author":"Dolan","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.01.032_bib0025","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.032_bib0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0045","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 Study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.anai.2018.01.032_bib0060","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0065","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.032_bib0070","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.032_bib0075","article-title":"Efficacy and Safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.anai.2018.01.032_bib0080","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0085","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.01.032_bib0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2018.01.032_bib0100","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0115","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0120","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0125","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis","volume":"140","author":"Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0130","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2018.01.032_bib0135","doi-asserted-by":"crossref","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2018.01.032_bib0140","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0145","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.anai.2017.09.056","article-title":"Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO","volume":"119","author":"Chipps","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.01.032_bib0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.chest.2016.09.023","article-title":"COUNTERPOINT: Will new anti-eosinophilic drugs be useful in asthma management? no","volume":"151","author":"Barnes","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.anai.2018.01.032_bib0160","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618300632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618300632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:19:07Z","timestamp":1761052747000},"score":24.250675,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618300632"}},"issued":{"date-parts":[[2018,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1081120618300632"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.01.032","ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in allergic and immunologic diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.01.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:29:49Z","timestamp":1760239789953,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1991,2,1]],"date-time":"1991-02-01T00:00:00Z","timestamp":665366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1991,2,1]],"date-time":"1991-02-01T00:00:00Z","timestamp":665366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[1991,2]]},"DOI":"10.1016\/s0889-8561(22)00315-0","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T17:26:28Z","timestamp":1656696388000},"page":"201-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Immunologic Lung Diseases"],"prefix":"10.1016","volume":"11","author":[{"given":"Raymond G.","family":"Slavin","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0889-8561(22)00315-0_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0272-6386(86)80151-2","article-title":"Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage","volume":"8","author":"Boyce","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/S0889-8561(22)00315-0_bib2","series-title":"Current Therapy of Respiratory Disease","article-title":"Goodpasture\u2019s syndrome","author":"Colman","year":"1989"},{"key":"10.1016\/S0889-8561(22)00315-0_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM198401193100304","article-title":"Interstitial lung diseases of unknown cause","volume":"310","author":"Crystal","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/S0889-8561(22)00315-0_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0091-6749(84)90077-0","article-title":"Hypersensitivity pneumonitis","volume":"74","author":"Fink","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0889-8561(22)00315-0_bib5","first-page":"444","article-title":"Diagnosis and management of allergic bronchopulmonary aspergillosis","volume":"56","author":"Greenberger","year":"1986","journal-title":"Ann Allergy"},{"key":"10.1016\/S0889-8561(22)00315-0_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1398-9995.1988.tb02040.x","article-title":"High-dose local steroid treatment in bronchopulmonary aspergillosis. A pilot study","volume":"43","author":"Heinig","year":"1988","journal-title":"Allergy"},{"key":"10.1016\/S0889-8561(22)00315-0_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease. Analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"4","author":"Johnson","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/S0889-8561(22)00315-0_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0091-6749(84)90482-2","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis","volume":"73","author":"Laufer","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0889-8561(22)00315-0_bib9","series-title":"Current Therapy of Respiratory Disease","article-title":"Sarcoidosis","author":"Lieberman","year":"1989"},{"key":"10.1016\/S0889-8561(22)00315-0_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7326\/0003-4819-96-3-286","article-title":"Allergic bronchopulmonary aspergillosis: Staging as an aid to management","volume":"96","author":"Patterson","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0889-8561(22)00315-0_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0091-6749(87)90285-5","article-title":"Prolonged evaluation of patients with corticosteroid asthma stage of allergic bronchopulmonary aspergillosis","volume":"80","author":"Patterson","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0889-8561(22)00315-0_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0091-6749(84)90089-7","article-title":"Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis","volume":"74","author":"Ricketti","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0889-8561(22)00315-0_bib13","first-page":"450","article-title":"Five-year follow-up of allergic bronchopulmonary aspergillosis","volume":"108","author":"Safirstein","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0889-8561(22)00315-0_bib14","first-page":"451","article-title":"Hypersensitivity pneumonitis\u2014general considerations","volume":"1","author":"Schatz","year":"1983","journal-title":"Clin Rev Allergy"},{"key":"10.1016\/S0889-8561(22)00315-0_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02992981","article-title":"Allergic bronchopulmonary aspergillosis","volume":"3","author":"Slavin","year":"1985","journal-title":"Clin Rev Allergy"},{"key":"10.1016\/S0889-8561(22)00315-0_bib16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/0091-6749(88)91044-5","article-title":"A pathological study of ABPA","volume":"81","author":"Slavin","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0889-8561(22)00315-0_bib17","series-title":"Current Therapy in Allergy, Immunology and Rheumatology","article-title":"Hypersensitivity pneumonitis","author":"Slavin","year":"1988"},{"key":"10.1016\/S0889-8561(22)00315-0_bib18","series-title":"Current Therapy of Respiratory Disease","article-title":"Allergic bronchopulmonary aspergillosis","author":"Slavin","year":"1989"},{"key":"10.1016\/S0889-8561(22)00315-0_bib19","first-page":"101","article-title":"Extrinsic allergic alveolitis\u2014management of established cases","volume":"123","author":"Terhko","year":"1982","journal-title":"Eur J Respir Dis"}],"container-title":["Immunology and Allergy Clinics of North America"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856122003150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856122003150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:49:14Z","timestamp":1760179754000},"score":24.241251,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856122003150"}},"issued":{"date-parts":[[1991,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991,2]]}},"alternative-id":["S0889856122003150"],"URL":"https:\/\/doi.org\/10.1016\/s0889-8561(22)00315-0","ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"published":{"date-parts":[[1991,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Immunologic Lung Diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0889-8561(22)00315-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1991 Elsevier B.V. Company. Published by Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T18:40:32Z","timestamp":1714588832174},"reference-count":105,"publisher":"Elsevier","isbn-type":[{"value":"9780323056595","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2009]]},"DOI":"10.1016\/b978-0-323-05659-5.00054-1","type":"book-chapter","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T19:24:01Z","timestamp":1333481041000},"page":"957-971","source":"Crossref","is-referenced-by-count":0,"title":["Immunologic Non-Asthmatic Diseases of the Lung"],"prefix":"10.1016","author":[{"given":"Michael C.","family":"Sneller","sequence":"first","affiliation":[]},{"given":"James H.","family":"Shelhamer","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/B978-0-323-05659-5.00054-1_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granuloamtosis","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0889-857X(05)70232-5","article-title":"Epidemiology of the vasculitides","volume":"27","author":"Gonzalez-Gay","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"10.1016\/B978-0-323-05659-5.00054-1_bib4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6","article-title":"Epidemiology of Wegener's granulomatosis in northern Norway","volume":"43","author":"Koldingsnes","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/art.20534","article-title":"Wegener's granulomatosis: possible role of environmental agents in its pathogenesis","volume":"51","author":"Albert","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/art.10830","article-title":"Are environmental factors important in primary systemic vasculitis? A case-control study","volume":"48","author":"Lane","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000478-199104000-00001","article-title":"Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients","volume":"15","author":"Travis","year":"1991","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/B978-0-323-05659-5.00054-1_bib8","first-page":"533","article-title":"Wegener's granulomatosis: pathology and review of the literature","volume":"58","author":"Godman","year":"1954","journal-title":"AMA Arch Pathol"},{"issue":"3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib9","first-page":"423","article-title":"Renal biopsy pathology in Wegener's granulomatosis","volume":"74","author":"Horn","year":"1974","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/B978-0-323-05659-5.00054-1_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500921X","article-title":"Pathogenesis of Wegener's granulomatosis: current concepts","volume":"7","author":"Sarraf","year":"2005","journal-title":"Expert Rev Mol Med"},{"issue":"7","key":"10.1016\/B978-0-323-05659-5.00054-1_bib11","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"Ludviksson","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I","article-title":"Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation","volume":"42","author":"Csernok","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/B978-0-323-05659-5.00054-1_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-123-12-199512150-00005","article-title":"The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis","volume":"123","author":"Rao","year":"1995","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/B978-0-323-05659-5.00054-1_bib14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A","article-title":"Antineutrophil cytoplasmic antibodies","volume":"41","author":"Hoffman","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/B978-0-323-05659-5.00054-1_bib15","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.153.3.1271","article-title":"Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa","volume":"153","author":"Porges","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2249.1994.tb06579.x","article-title":"Binding of proteinase 3 and myeloperoxidase to endothelial cells: ANCA-mediated endothelial damage through ADCC?","volume":"97","author":"Ballieux","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-05659-5.00054-1_bib18","first-page":"335","article-title":"Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells","volume":"141","author":"Savage","year":"1992","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/B978-0-323-05659-5.00054-1_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/B978-0-323-05659-5.00054-1_bib20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.1780360312","article-title":"Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis","volume":"36","author":"Kerr","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/B978-0-323-05659-5.00054-1_bib22","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.1780391020","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis","volume":"39","author":"Langford","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/B978-0-323-05659-5.00054-1_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","article-title":"Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients","volume":"14","author":"Devaney","year":"1990","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3949\/ccjm.65.3.135","article-title":"The diagnostic utility of c-ANCA in Wegener's granulomatosis","volume":"65","author":"Langford","year":"1998","journal-title":"Cleve Clin J Med"},{"issue":"8980","key":"10.1016\/B978-0-323-05659-5.00054-1_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(95)91555-9","article-title":"A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis","volume":"346","author":"Rao","year":"1995","journal-title":"Lancet"},{"issue":"5091","key":"10.1016\/B978-0-323-05659-5.00054-1_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"34","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener's granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/B978-0-323-05659-5.00054-1_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/B978-0-323-05659-5.00054-1_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/B978-0-323-05659-5.00054-1_bib32","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/B978-0-323-05659-5.00054-1_bib33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.1780310822","article-title":"The role of trimethoprim-sulfamethoxazole in the treatment of Wegener's granulomatosis","volume":"31","author":"Leavitt","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Anon","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0197-2456(02)00209-X","article-title":"Design of the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"23","author":"WGET Research Group","year":"2002","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/B978-0-323-05659-5.00054-1_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/B978-0-323-05659-5.00054-1_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.20928","article-title":"Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register","volume":"53","author":"Reinhold-Keller","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/B978-0-323-05659-5.00054-1_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib46","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0046-8177(83)80162-2","article-title":"Pulmonary angiitis and granulomatosis revisited","volume":"14","author":"Churg","year":"1983","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/B978-0-323-05659-5.00054-1_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","article-title":"Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome","volume":"44","author":"Kiene","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/B978-0-323-05659-5.00054-1_bib48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9343(03)00359-0","article-title":"Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists","volume":"115","author":"Keogh","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib49","first-page":"277","article-title":"Allergic granulomatosis, allergic angiitis and periarteritis nodosa","volume":"27","author":"Churg","year":"1951","journal-title":"Am J Pathol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","article-title":"Statement on sarcoidosis","volume":"160","author":"Hunninghake","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization","volume":"145","author":"Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib52","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1164\/ajrccm.164.11.2106001","article-title":"Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS)","volume":"164","author":"Rybicki","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib53","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1164\/rccm.200402-249OC","article-title":"A case control etiologic study of sarcoidosis: environmental and occupational risk factors","volume":"170","author":"Newman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib54","first-page":"557","volume":"152","author":"Martinetti","year":"1995","journal-title":"\u2018The sarcoidosis map\u2019: a joint survey of clinical and immunogenetic findings in two European countries"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002281-200001000-00012","article-title":"New pathogenetic insights into the sarcoid granuloma","volume":"12","author":"Agostini","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1378\/chest.104.2.352","article-title":"Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis","volume":"104","author":"Winterbauer","year":"1993","journal-title":"Chest"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/thorax.56.6.487","article-title":"Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis","volume":"56","author":"Mollers","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib58","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1001\/jama.289.24.3300","volume":"289","author":"Thomas","year":"2003","journal-title":"Sarcoidosis. JAMA"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib59","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2003-42375","article-title":"Computed tomographic scanning in sarcoidosis","volume":"24","author":"Lynch","year":"2003","journal-title":"Semin Resp Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0272-5231(05)70417-2","article-title":"Pulmonary sarcoidosis","volume":"18","author":"Lynch","year":"1997","journal-title":"Clin Chest Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib62","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1164\/arrd.1980.122.5.721","article-title":"Transbronchial lung biopsy in sarcoidosis","volume":"122","author":"Gilman","year":"1980","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib63","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1378\/chest.124.6.2126","article-title":"The value of flexible transbronchial needle aspiration in the diagnosis of stage 1 sarcoidosis","volume":"124","author":"Trisolini","year":"2003","journal-title":"Chest"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib64","first-page":"147","article-title":"Transbronchial needle aspiration improves the diagnostic yield of bronchoscopy in sarcoidosis","volume":"21","author":"Trisolini","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib65","series-title":"Non-neoplastic disorders of the lower respiratory tract","author":"Travis","year":"2002"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1164\/rccm.200608-1197OC","article-title":"Sex specific manifestations of Lofgren's syndrome","volume":"175","author":"Grunewald","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib67","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib68","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1164\/rccm.200512-1839OC","article-title":"Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis","volume":"174","author":"Hill","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccm.2004.04.006","article-title":"Pulmonary sarcoidosis","volume":"25","author":"Baughman","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib70","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jama.287.10.1301","article-title":"Corticosteroid therapy in pulmonary sarcoidosis: a systematic review","volume":"287","author":"Paramothayaan","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib71","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib72","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003536.pub2","article-title":"Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis","volume":"3","author":"Paramothayan","year":"2006","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib74","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","article-title":"Prolonged use of methotrexate for sarcoidosis","volume":"155","author":"Lower","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib75","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0025-6196(11)62114-9","article-title":"Diagnosis and treatment of allergic bronchopulmonary aspergillosis","volume":"76","author":"Vlahakis","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 3","key":"10.1016\/B978-0-323-05659-5.00054-1_bib76","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis \u2013 state of the art: Cystic Fibrosis Foundation Consensus Conference","volume":"37","author":"Stevens","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib77","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1080\/13693780500064763","article-title":"Aspergillus antigens: which are important?","volume":"43","author":"Kurup","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2006-939521","article-title":"Allergic bronchopulmonary aspergillosis","volume":"27","author":"Gibson","year":"2006","journal-title":"Semin Resp Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib79","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1164\/rccm.200508-1271OC","article-title":"Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"173","author":"Hartl","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-7961-4-3","article-title":"Il-4 Alpha chain receptor (IL-4R\u03b1) polymorphisms in allergic bronchopulmonary aspergillosis","volume":"4","author":"Knutsen","year":"2006","journal-title":"Clin Mol Allergy"},{"issue":"Suppl 1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib81","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1080\/13693780500052255","article-title":"Pathophysiology and immunology of allergic bronchopulmonary aspergillosis","volume":"43","author":"Moss","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib82","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2214\/ajr.173.4.10511153","article-title":"Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients","volume":"173","author":"Ward","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib83","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/thx.49.6.586","article-title":"Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus funigatis","volume":"49","author":"Angus","year":"1994","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/B978-0-323-05659-5.00054-1_bib84","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1080\/13693780500064771","article-title":"The radiological spectrum of pulmonary aspergillosis","volume":"43","author":"Green","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib85","first-page":"333","article-title":"Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis","volume":"70","author":"Greenberger","year":"1993","journal-title":"Ann Allergy"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib86","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7326\/0003-4819-96-3-286","article-title":"Allergic bronchopulmonary aspergillosis: staging as an aid to management","volume":"96","author":"Patterson","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib87","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1164\/rccm.200603-423OC","article-title":"Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis","volume":"174","author":"Kraemer","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0091-6749(84)90089-7","article-title":"Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis","volume":"74","author":"Ricketti","year":"1984","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib89","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib90","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ki.1978.72","article-title":"Goodpasture's syndrome: an analysis of 29 cases","volume":"13","author":"Teague","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib91","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(01)06077-9","article-title":"Goodpasture's disease","volume":"358","author":"Salama","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib93","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib94","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1999.055003926.x","article-title":"Goodpasture antigen: expression of the full-length \u03b13(IV) chain of collagen IV and localization of the epitopes exclusively to the noncollagenous domain","volume":"55","author":"Leinonen","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib95","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/S0270-9295(03)00131-1","article-title":"Pathogenesis of Goodpasture syndrome: a molecular perspective","volume":"23","author":"Borza","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib96","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1046\/j.1523-1755.1999.00720.x","article-title":"The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity","volume":"56","author":"Phelps","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib97","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1681\/ASN.V1291908","article-title":"In: Goodpasture's disease, CD4+ T cells escape thymic deletion and are reactive with the autoantigen \u03b13(IV)NC1","volume":"12","author":"Salama","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib98","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib99","series-title":"Non-neoplastic disorders of the lower respiratory tract","author":"Travis","year":"2002"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0272-6386(86)80151-2","article-title":"Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage","volume":"8","author":"Boyce","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib101","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archinte.1996.00440040118013","article-title":"The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition","volume":"156","author":"Niles","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib102","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/bmme.1996.0064","article-title":"Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis","volume":"59","author":"Litwin","year":"1996","journal-title":"Biochem Mol Med"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib103","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib104","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.1973.14","article-title":"Anti-glomerular basement membrane antibody-induced glomerulonephritis","volume":"3","author":"Wilson","year":"1973","journal-title":"Kidney Int"},{"key":"10.1016\/B978-0-323-05659-5.00054-1_bib105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(96)90169-9","article-title":"Recurrent Goodpasture's disease","volume":"27","author":"Levy","year":"1996","journal-title":"Am J Kidney Dis"}],"container-title":["Middleton's Allergy: Principles and Practice"],"language":"en","deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T18:20:40Z","timestamp":1687371640000},"score":24.237183,"resource":{"primary":{"URL":"https:\/\/www.elsevier.com\/books-and-journals\/deleted-doi"}},"issued":{"date-parts":[[2009]]},"ISBN":["9780323056595"],"references-count":105,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-05659-5.00054-1","published":{"date-parts":[[2009]]}},{"indexed":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T05:08:55Z","timestamp":1734239335796,"version":"3.30.2"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1097\/00130832-200112000-00008","type":"journal-article","created":{"date-parts":[[2003,11,11]],"date-time":"2003-11-11T14:03:45Z","timestamp":1068559425000},"page":"541-543","source":"Crossref","is-referenced-by-count":1,"title":["Immunologic treatment of allergic diseases"],"prefix":"10.1097","volume":"1","author":[{"given":"David","family":"Broide","sequence":"first","affiliation":[]},{"given":"Hans-J\u00f8rgen","family":"Malling","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-8-20061207","first-page":"1","volume":"53","author":"Bousquet","year":"1998","journal-title":"Allergy"},{"key":"R2-8-20061207","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1398-9995.1998.tb04082.x","volume":"53","author":"Malling","year":"1998","journal-title":"Allergy"},{"key":"R3-8-20061207","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/0-306-46830-1_9","volume":"478","author":"Bjorksten","year":"2000","journal-title":"Adv Exp Med Biol"},{"key":"R4-8-20061207","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1034\/j.1600-065X.2001.790112.x","volume":"179","author":"Valenta","year":"2001","journal-title":"Immunol Rev"},{"key":"R5-8-20061207","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000024403","volume":"122","author":"Haselden","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"R6-8-20061207","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.4049\/jimmunol.161.12.7054","volume":"161","author":"Broide","year":"1998","journal-title":"J Immunol"},{"key":"R8-8-20061207","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1067\/mai.2001.115624","volume":"107","author":"Borish","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"R9-8-20061207","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"R10-8-20061207","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1067\/mai.2001.116002","volume":"107","author":"Lee","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"R11-8-20061207","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/j.1398-9995.1998.tb03793.x","volume":"53","author":"Malling","year":"1998","journal-title":"Allergy"}],"container-title":["Current Opinion in Allergy and Clinical Immunology"],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130832-200112000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T09:47:24Z","timestamp":1734169644000},"score":24.192543,"resource":{"primary":{"URL":"http:\/\/journals.lww.com\/00130832-200112000-00008"}},"subtitle":[""],"issued":{"date-parts":[[2001,12]]},"references-count":10,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1097\/00130832-200112000-00008","ISSN":["1528-4050"],"issn-type":[{"type":"print","value":"1528-4050"}],"published":{"date-parts":[[2001,12]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:13:35Z","timestamp":1757614415904,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00004-7","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:25:30Z","timestamp":1666347930000},"page":"89-117","source":"Crossref","is-referenced-by-count":0,"title":["The allergy and immunology history and physical"],"prefix":"10.1016","author":[{"given":"Hanadys","family":"Ale","sequence":"first","affiliation":[]},{"given":"Marlen","family":"Rodriguez","sequence":"additional","affiliation":[]},{"given":"Wilfredo","family":"Cosme-Blanco","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00004-7_bib1","first-page":"559","article-title":"Relevance of medical semiology in the technological era","volume":"148","author":"Laso Guzman","year":"2017","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00004-7_bib2","first-page":"163","article-title":"Contributions of the history, physical examination, and laboratory investigation in making medical diagnoses","volume":"156","author":"Peterson","year":"1992","journal-title":"West J Med"},{"key":"10.1016\/B978-0-323-95061-9.00004-7_bib3","unstructured":"Bickley LS, Szilagyi PG, Bates B. Bates\u2019 guide to physical examination and history taking. Lippincott Williams & Wilkins; 2008."},{"key":"10.1016\/B978-0-323-95061-9.00004-7_bib4","unstructured":"Bowling B, Kanski JJ. Kanski\u2019s clinical ophthalmology: a systematic approach. Edinburgh: Elsevier; 2016."},{"key":"10.1016\/B978-0-323-95061-9.00004-7_bib5","unstructured":"Kellerman RD, Rakel D. Conn\u2019s current therapy 2020. Philadelphia: Elsevier; 2020."},{"key":"10.1016\/B978-0-323-95061-9.00004-7_bib6","unstructured":"McIntire SC, Nowalk AJ, Zitelli BJ. Zitelli and Davis\u2019 atlas of pediatric physical diagnosis. Elsevier Health Sciences; 2018."},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00004-7_bib7","first-page":"485","article-title":"Ocular allergy: diagnosis and treatment","volume":"18","author":"Butrus","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00004-7_bib8","first-page":"942","volume":"58","author":"Nelson textbook of paediatrics","year":"1983","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00004-7_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1067\/mai.2000.111238","article-title":"Allergic and immunologic disorders of the eye. Part II: Ocular allergy","volume":"106","author":"Bielory","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00004-7_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.ASW.0000416010.08584.18","article-title":"Identifying primary and secondary lesions","volume":"25","author":"Hess","year":"2012","journal-title":"Adv Skin Wound Care"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00004-7_bib11","first-page":"598","article-title":"Palpation of the skin\u2014an important issue","volume":"99","author":"Cox","year":"2006","journal-title":"J R Soc Med"},{"year":"2020","series-title":"Dermatographism","author":"Nobles","key":"10.1016\/B978-0-323-95061-9.00004-7_bib12"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00004-7_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.1971.tb14027.x","article-title":"The incidence and other aspects of factitious wealing (dermographism)","volume":"85","author":"Kirby","year":"1971","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00004-7_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0378-6323.35751","article-title":"Darier\u2019s sign","volume":"73","author":"Surjushe","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00004-7_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/archpedi.1997.02170400110025","article-title":"Nelson textbook of pediatrics","volume":"151","author":"Pomerance","year":"1997","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"6 Suppl.","key":"10.1016\/B978-0-323-95061-9.00004-7_bib16","first-page":"S1","article-title":"Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel","volume":"126","author":"Panel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00004-7_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1399-3038.2007.00688.x","article-title":"History of respiratory infections in the first 12 yr among children from a birth cohort","volume":"19","author":"Gruber","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00004-7_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pcl.2008.10.004","article-title":"Recurrent respiratory infections","volume":"56","author":"Bush","year":"2009","journal-title":"Pediatr Clin North Am"},{"issue":"6B","key":"10.1016\/B978-0-323-95061-9.00004-7_bib19","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1016\/S0002-9343(99)80307-6","article-title":"Viral respiratory infections in the community: epidemiology, agents, and interventions","volume":"99","author":"Monto","year":"1995","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00004-7_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/adc.73.4.281","article-title":"Acute respiratory infection: a global challenge","volume":"73","author":"Campbell","year":"1995","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00004-7_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00004-7_bib22","unstructured":"Foundation T.J.M. The 10 warning signs of primary immunodeficiency. <http:\/\/www.info4pi.org\/library\/educational-materials\/10-warning-signs>; 2016 [accessed 06.06.20]."}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:18:07Z","timestamp":1757056687000},"score":24.148514,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000047"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":22,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00004-7","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T05:11:33Z","timestamp":1715490693708},"reference-count":150,"publisher":"Elsevier","isbn-type":[{"value":"9780323085939","type":"print"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2014]]},"DOI":"10.1016\/b978-0-323-08593-9.00040-1","type":"book-chapter","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T15:09:17Z","timestamp":1604502557000},"page":"618-637","source":"Crossref","is-referenced-by-count":1,"title":["Allergic and Immunologic Diseases of the Eye"],"prefix":"10.1016","author":[{"given":"Neal P.","family":"Barney","sequence":"first","affiliation":[]},{"given":"Ellen B.","family":"Cook","sequence":"additional","affiliation":[]},{"given":"James L.","family":"Stahl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.iac.2007.12.005","article-title":"Allergic conjunctivitis","volume":"28","author":"Bielory","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib2","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1073\/pnas.83.12.4464","article-title":"Two types of human mast cells that have distinct neutral protease compositions","volume":"83","author":"Irani","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1 Pt 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0091-6749(91)90221-9","article-title":"Mast cell numbers and staining characteristics in the normal and allergic human conjunctiva","volume":"87","author":"Morgan","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0091-6749(05)80120-4","article-title":"Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis","volume":"86","author":"Irani","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2222.1995.tb01001.x","article-title":"Mast cell distribution and neutral protease expression in acute and chronic allergic conjunctivitis","volume":"25","author":"Baddeley","year":"1995","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0161-6420(80)35158-0","article-title":"Tear histamine levels in vernal conjunctivitis and other ocular inflammations","volume":"87","author":"Abelson","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000076112","article-title":"Quantitative determination of histamine in tears during conjunctivitis by a novel HPLC method","volume":"36","author":"Venza","year":"2004","journal-title":"Ophthalmic Res"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib8","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/S0161-6420(90)32362-X","article-title":"The level of tryptase in human tears. An indicator of activation of conjunctival mast cells","volume":"97","author":"Butrus","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s00417-004-0943-6","article-title":"Eotaxin-1 (CCL11) up-regulation in tears during seasonal allergic conjunctivitis","volume":"242","author":"Eperon","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib10","first-page":"13","article-title":"[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis.]","volume":"110","author":"Muromoto","year":"2006","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib11","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-2222.1997.tb01179.x","article-title":"Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva","volume":"27","author":"Macleod","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2222.1999.00365.x","article-title":"Tumour necrosis factor alpha (TNFalpha) in tears of atopic patients after conjunctival allergen challenge","volume":"29","author":"Vesaluoma","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2222.2000.00699.x","article-title":"Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis","volume":"30","author":"Uchio","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2249.1995.tb03796.x","article-title":"Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis","volume":"102","author":"Fujishima","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0022-1759(01)00407-0","article-title":"Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics","volume":"254","author":"Cook","year":"2001","journal-title":"J Immunol Methods"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib16","first-page":"17673","article-title":"Inflammatory cytokines in normal human tears","author":"Nakamura","year":"1998","journal-title":"Curr Eye Res"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib17","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1167\/iovs.06-0088","article-title":"Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment","volume":"47","author":"Cook","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib19","first-page":"35","article-title":"In vivo evaluation of conjunctival expression of ICAM-1 and CD23 utilizing impression cytology combined with FACS analysis","volume":"110","author":"Cook","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1081-1206(10)62926-2","article-title":"Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells","volume":"87","author":"Cook","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1081-1206(10)61712-7","article-title":"The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells","volume":"92","author":"Cook","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2 Suppl 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib22","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1081-1206(10)60898-8","article-title":"Update on sublingual immunotherapy","volume":"96","author":"Potter","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0002-9394(53)92176-X","article-title":"Atopic keratoconjunctivitis","volume":"36","author":"Hogan","year":"1953","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib24","first-page":"21","article-title":"Ocular complications of atopic dermatitis","volume":"19","author":"Garrity","year":"1984","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.iac.2010.06.003","article-title":"Epidemiology of atopic dermatitis and atopic march in children","volume":"30","author":"Spergel","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0021-5155(98)00061-6","article-title":"Ocular surface disease in atopic dermatitis","volume":"43","author":"Dogru","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1590\/S0004-27492009000600012","article-title":"Atopic keratoconjunctivitis in patients of the pediatric dermatology ambulatory in a reference center","volume":"72","author":"Moscovici","year":"2009","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0161-6420(90)32477-6","article-title":"Atopic keratoconjunctivitis","volume":"97","author":"Foster","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0161-6420(98)94017-9","article-title":"Long-term follow-up of patients with atopic keratoconjunctivitis","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0161-6420(91)32322-4","article-title":"Clinical features of atopic keratoconjunctivitis","volume":"98","author":"Tuft","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0091-6749(05)80120-4","article-title":"Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis","volume":"86","author":"Irani","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0161-6420(91)32154-7","article-title":"Immunopathology of atopic keratoconjunctivitis","volume":"98","author":"Foster","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib33","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ophtha.2008.05.010","article-title":"Corneal in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis","volume":"115","author":"Hu","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1365-2222.2006.02581.x","article-title":"Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis","volume":"36","author":"Dogru","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1398-9995.2007.01414.x","article-title":"The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis","volume":"62","author":"Hu","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib36","first-page":"1379","article-title":"Conjunctival in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis","volume":"13","author":"Hu","year":"2007","journal-title":"Mol Vis"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0091-6749(98)70023-5","article-title":"Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases","volume":"102","author":"Hingorani","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Pt 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0091-6749(97)70279-3","article-title":"T-cell cytokines in chronic allergic eye disease","volume":"100","author":"Metz","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib39","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0091-6749(96)70103-3","article-title":"Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease","volume":"98","author":"Metz","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib40","series-title":"The cornea","first-page":"573","article-title":"Vernal and atopic conjunctivitis","author":"Barney","year":"2011"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00417-006-0285-7","article-title":"Th1- and Th2-type cytokines in chronic ocular allergy","volume":"244","author":"Leonardi","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ajo.2008.05.012","article-title":"Acquisition of vernal and atopic keratoconjunctivitis after bone marrow transplantation","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0002-9394(02)01726-9","article-title":"Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis","volume":"134","author":"Messmer","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib44","series-title":"Allergy and immunology of the eye","first-page":"76","article-title":"Diseases affecting the eye and skin","author":"Friedlaender","year":"1979"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/00003226-199511000-00015","article-title":"Penetrating keratoplasty in atopic keratoconjunctivitis","volume":"14","author":"Ghoraishi","year":"1995","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib46","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/archopht.1954.00920050858006","article-title":"Cataract and retinal detachment associated with atopic dermatitis","volume":"52","author":"Hurlbut","year":"1961","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2133.1995.tb02710.x","article-title":"Atopic retinal detachment. Report of four cases and a review of the literature","volume":"133","author":"Yoneda","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib48","first-page":"921","article-title":"Deratose, katarakt und ablatio retinae","volume":"152","author":"Klemens","year":"1966","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxn137","article-title":"Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1\/CCR3 blockade","volume":"21","author":"Miyazaki","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib51","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0161-6420(97)30144-4","article-title":"Systemic cyclosporin A in severe atopic keratoconjunctivitis","volume":"104","author":"Hoang-Xuan","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib52","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib53","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.ico.0000240091.11854.14","article-title":"Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis","volume":"25","author":"Stumpf","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib54","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/ICO.0b013e318172fbb1","article-title":"Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis","volume":"27","author":"Anzaar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0161-6420(88)33155-6","article-title":"Plasmapheresis treatment in patients with severe atopic keratoconjunctivitis","volume":"95","author":"Aswad","year":"1988","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(84)90438-0","article-title":"Keratoepithelioplasty","volume":"97","author":"Thoft","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis: a major review","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib58","series-title":"Vernal conjunctivitis","author":"Beigelman","year":"1950"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib59","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib61","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0002-9394(79)90247-2","article-title":"Vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis compared and contrasted","volume":"87","author":"Allansmith","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib62","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjo.79.5.482","article-title":"Collagen types I and III in giant papillae of vernal keratoconjunctivitis","volume":"79","author":"Leonardi","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib63","first-page":"146","article-title":"Neutral proteases as indicators of human mast cell heterogeneity","volume":"27","author":"Irani","year":"1990","journal-title":"Monogr Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib64","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00003226-200110000-00014","article-title":"Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage","volume":"20","author":"Miyoshi","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib65","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archopht.1981.03930010884019","article-title":"Density of goblet cells in vernal conjunctivitis and contact lens- associated giant papillary conjunctivitis","volume":"99","author":"Allansmith","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/archopht.124.4.462","article-title":"Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis","volume":"124","author":"Motterle","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib67","first-page":"1594","article-title":"Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis","volume":"12","author":"Micera","year":"2006","journal-title":"Mol Vis"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib68","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF02169416","article-title":"Immunopathological study of vernal keratoconjunctivitis","volume":"227","author":"Abu el-Asrar","year":"1989","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib69","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.ophtha.2005.04.009","article-title":"Expression of Toll-like receptors in healthy and allergic conjunctiva","volume":"112","author":"Bonini","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9394(14)73261-1","article-title":"Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis","volume":"108","author":"Trocme","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib9002","first-page":"4175","article-title":"Growth factors and collagen distribution in vernal keratoconjunctivitis","volume":"41","author":"Leonardi","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0167-5699(10)80004-0","article-title":"Regulation and deregulation of human IgE synthesis","volume":"11","author":"Romagnani","year":"1990","journal-title":"Immunol Today"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib72","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1046\/j.1365-2222.1999.00585.x","article-title":"Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease","volume":"29","author":"Calder","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib73","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1365-2222.2007.02732.x","article-title":"Matrix metalloproteases in vernal keratoconjunctivitis, nasal polyps and allergic asthma","volume":"37","author":"Leonardi","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib74","first-page":"s1024","article-title":"Corneal epithelial expressio of ICAM-1 in vernal keratoconjunctivitis","volume":"36","author":"Temprano","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib75","first-page":"s698","article-title":"Eosinophil peroxidase and eosinophil-derived neurotoxin toxicity on cultured human corneal epithelium","volume":"36","author":"Hallberg","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib76","first-page":"s699","article-title":"The barrier properties of an in vitro human corneal epithelial model are not altered by eosinophil major basic protein or eosinophil catiaonic protein","volume":"36","author":"Ward","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00143810","article-title":"A contribution to the immunopathology of vernal keratoconjunctivitis","volume":"53","author":"Sompolinsky","year":"1982","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib78","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0091-6749(80)90057-3","article-title":"Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis","volume":"66","author":"Ballow","year":"1980","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib79","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10384-007-0461-2","article-title":"Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients","volume":"51","author":"Shoji","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000024055","article-title":"Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling","volume":"118","author":"Bonini","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000232727","article-title":"Studies on histamine and histaminase in spring catarrh (vernal conjunctivitis)","volume":"64","author":"Mukhopadhyay","year":"1981","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib82","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0161-6420(84)34178-1","article-title":"Vernal conjunctivitis in the hyperimmunoglobulinemia E syndrome","volume":"91","author":"Butrus","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib83","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004397-198802840-00009","article-title":"Vernal keratoconjunctivitis","volume":"28","author":"Buckley","year":"1988","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib84","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2222.1999.00501.x","article-title":"Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis","volume":"29","author":"Verin","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib85","first-page":"593","article-title":"Sur le catarrhe printanier","volume":"30","author":"Trantas","year":"1910","journal-title":"Arch Ophthalmol (Paris)"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib86","series-title":"Advances in immunology and immunopathology of the eye","article-title":"Pathology of corneal plaque in vernal keratoconjunctivitis","author":"Rahi","year":"1985"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib87","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/bjo.64.7.483","article-title":"Clinical trial with 2% sodium cromoglycate (Opticrom) in vernal kerato\u00adconjunctivitis","volume":"64","author":"El Hennawi","year":"1980","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9394(14)74850-0","article-title":"Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis","volume":"90","author":"Foster","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib89","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.83.2.180","article-title":"Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis","volume":"83","author":"Tabbara","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib90","first-page":"314","article-title":"Evaluation of combined systemic aspirin and cromolyn sodium in intractable vernal catarrh","volume":"22","author":"Chaudhary","year":"1990","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib91","first-page":"508","article-title":"A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis","volume":"115","author":"Takamura","year":"2011","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib92","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00347-001-0600-y","article-title":"Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis","volume":"99","author":"Tomida","year":"2002","journal-title":"Ophthalmologe"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib93","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Pt 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/eye.1997.14","article-title":"Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis","volume":"11","author":"Mendicute","year":"1997","journal-title":"Eye"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib96","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00003226-199309000-00008","article-title":"Topical cyclosporin A in the treatment of anterior segment inflammatory disease","volume":"12","author":"Holland","year":"1993","journal-title":"Cornea"},{"issue":"Pt 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib98","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000050876","article-title":"Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis","volume":"215","author":"Avunduk","year":"2001","journal-title":"Ophthalmologica"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib99","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis","volume":"101","author":"BenEzra","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2003.10.065","article-title":"Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment","volume":"113","author":"Vichyanond","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00417-007-0682-6","article-title":"Preliminary evidence of the efficacy of probiotic eye-drop treatment in patients with vernal keratoconjunctivitis","volume":"246","author":"Iovieno","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib102","first-page":"215","article-title":"Vernal keratoconjunctivitis","volume":"81","author":"Jones","year":"1961","journal-title":"Trans Ophthalmol Soc UK"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib103","first-page":"105","article-title":"Phototherapeutic keratectomy in the treatment of corneal surface disorders in children","volume":"58","author":"Autrata","year":"2002","journal-title":"Cesk Slov Oftalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib104","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0161-6420(01)00622-4","article-title":"Amniotic membrane transplantation in the management of shield ulcers of vernal kera\u00adtoconjunctivitis","volume":"108","author":"Sridhar","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib105","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00002341-200011000-00007","article-title":"Surgical resection of giant papillae and autologous conjunctival graft in patients with severe vernal keratoconjunctivitis and giant papillae","volume":"16","author":"Nishiwaki-Dantas","year":"2000","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib106","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1034\/j.1600-0420.1999.770505.x","article-title":"Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis","volume":"77","author":"Saini","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib107","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0002-9394(14)70271-5","article-title":"Supratarsal injection of corticosteroid in the treatment of refractory vernal kerato\u00adconjunctivitis","volume":"121","author":"Holsclaw","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib108","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00003226-200405000-00003","article-title":"A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis","volume":"23","author":"Tanaka","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.ico.0000183533.14899.8d","article-title":"Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications","volume":"25","author":"Tanaka","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib110","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0002-9394(77)90137-4","article-title":"Giant papillary conjunctivitis in contact lens wearers","volume":"83","author":"Allansmith","year":"1977","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib111","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00006324-199003000-00008","article-title":"Association of giant papillary conjunctivitis with seasonal allergies","volume":"67","author":"Begley","year":"1990","journal-title":"Optom Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib112","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004397-198802840-00010","article-title":"Giant papillary conjunctivitis","volume":"28","author":"Allansmith","year":"1988","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1076\/ceyr.22.4.253.5504","article-title":"Delayed tear clearance in contact lens associated papillary conjunctivitis","volume":"22","author":"Chang","year":"2001","journal-title":"Curr Eye Res"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib114","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archopht.1981.03930020140019","article-title":"Mast cell ultrastructure. Comparison in contact lens-associated giant papillary conjunctivitis and vernal conjunctivitis","volume":"99","author":"Henriquez","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1076\/ocii.11.3.223.17350","article-title":"Tear eotaxin levels in giant papillary conjunctivitis associated with ocular prosthesis","volume":"11","author":"Sarac","year":"2003","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-198631020-00003","article-title":"Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease","volume":"31","author":"Sorkin","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib117","first-page":"443","article-title":"Pathology and treatment of giant papillary conjunctivitis. I. The U.S. perspective","volume":"9","author":"Allansmith","year":"1987","journal-title":"Clin Ther"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib118","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1001\/archopht.1982.01030040586005","article-title":"Cromolyn treatment of giant papillary conjunctivitis","volume":"100","author":"Meisler","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib119","first-page":"346","article-title":"Treatment of contact lens-induced giant papillary conjunctivitis","volume":"10","author":"Donshik","year":"1984","journal-title":"CLAO J"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib120","first-page":"31","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis","volume":"23","author":"Asbell","year":"1997","journal-title":"CLAO J"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib122","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","article-title":"Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib123","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1398-9995.1997.tb04810.x","article-title":"The eosinophil and the eye","volume":"52","author":"Bonini","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000310855","article-title":"Quantitative evaluation of inflammatory cells in seasonal allergic conjunctivitis","volume":"211","author":"Nomura","year":"1997","journal-title":"Ophthalmologica"},{"issue":"1 Pt 1","key":"10.1016\/B978-0-323-08593-9.00040-1_bib125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0091-6749(93)90036-F","article-title":"Precision of conjunctival provocation tests in right and left eyes","volume":"92","author":"Aichane","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib126","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/S0161-6420(90)32362-X","article-title":"The level of tryptase in human tears. An indicator of activation of conjunctival mast cells","volume":"97","author":"Butrus","year":"1990","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib127","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0091-6749(90)90075-F","article-title":"Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen","volume":"85","author":"Proud","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"21 Suppl","key":"10.1016\/B978-0-323-08593-9.00040-1_bib128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1398-9995.1995.tb04251.x","article-title":"Therapeutic considerations: symptoms, cells and mediators","volume":"50","author":"Lightman","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib129","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00018-011-0846-8","article-title":"Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany","volume":"69","author":"Peiser","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.all.0000244799.33734.d4","article-title":"Ocular cicatricial pemphigoid","volume":"6","author":"Hingorani","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib131","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib132","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.1971.04000230009002","article-title":"Benign mucous membrane pemphigoid","volume":"104","author":"Hardy","year":"1971","journal-title":"Arch Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib133","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.ophtha.2006.03.048","article-title":"Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid","volume":"113","author":"Thorne","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib134","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00128071-200506020-00004","article-title":"Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches","volume":"6","author":"Sacher","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib135","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.rdc.2007.08.002","article-title":"Scleritis and peripheral ulcerative keratitis","volume":"33","author":"Galor","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib136","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00003226-200009000-00008","article-title":"Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection","volume":"19","author":"Dana","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib137","first-page":"7","article-title":"Mooren's ulcer: current concepts in management","volume":"45","author":"Sangwan","year":"1997","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib138","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0161-6420(85)33845-9","article-title":"Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer","volume":"92","author":"Foster","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib139","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/IAI.7.4.597-599.1973","article-title":"Immunity to chlamydial infections of the eye. II. Studies of passively transferred serum antibody in resistance to infection with guinea pig inclusion conjunctivitis","volume":"7","author":"Watson","year":"1973","journal-title":"Infect Immun"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","article-title":"Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression","volume":"91","author":"Foster","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib141","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(00)00710-8","article-title":"Episcleritis and scleritis: clinical features and treatment results","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib142","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","article-title":"Clinical characteristics of a large cohort of patients with scleritis and episcleritis","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib143","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archopht.117.7.966","article-title":"Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis","volume":"117","author":"Croasdale","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib144","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0161-6420(95)30963-3","article-title":"Therapy of nonnecrotizing anterior scleritis with subconjunctival corticosteroid injection","volume":"102","author":"Tu","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-9071.2006.01225.x","article-title":"Biologic therapies for inflammatory eye disease","volume":"34","author":"Lim","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib146","first-page":"10","article-title":"Effects of cyclosporine on T-cell subsets in experimental autoimmune uveitis","volume":"26","author":"Nussenblatt","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib147","first-page":"226","article-title":"Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats","volume":"26","author":"Mochizuki","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004397-199303340-00005","article-title":"Clinical use of cyclosporine in ocular disease","volume":"33","author":"de Smet","year":"1993","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib149","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/B978-0-323-08593-9.00040-1_bib150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Callejas-Rubio","year":"2008","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Middleton's Allergy"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323085939000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323085939000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T09:48:00Z","timestamp":1613987280000},"score":24.14168,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323085939000401"}},"issued":{"date-parts":[[2014]]},"ISBN":["9780323085939"],"references-count":150,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-08593-9.00040-1","published":{"date-parts":[[2014]]}},{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:13:53Z","timestamp":1757614433004,"version":"3.44.0"},"reference-count":97,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323950619"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/b978-0-323-95061-9.00017-5","type":"book-chapter","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:38:42Z","timestamp":1666348722000},"page":"471-510","source":"Crossref","is-referenced-by-count":0,"title":["Approach to the rash from an allergy and immunology perspective"],"prefix":"10.1016","author":[{"given":"Sonam","family":"Sani","sequence":"first","affiliation":[]},{"given":"Luz","family":"Fonacier","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2009.10.002","article-title":"From atopic dermatitis to asthma: the atopic march","volume":"105","author":"Spergel","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2133.2003.05243.x","article-title":"Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population","volume":"148","author":"Kato","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2012.12.1563","article-title":"The cutaneous innate immune response in patients with atopic dermatitis","volume":"131","author":"Kuo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.anai.2018.03.003","article-title":"Contact dermatitis and patch testing for the allergist","volume":"120","author":"Fonacier","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2007.00409.x","article-title":"Irritant contact dermatitis: a review","volume":"49","author":"Slodownik","year":"2008","journal-title":"Australas J Dermatol"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00017-5_bib9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/archderm.1991.01680090122016","article-title":"Recent developments in the pathogenesis of allergic contact dermatitis","volume":"127","author":"Kalish","year":"1991","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib10","first-page":"296","article-title":"Contact dermatitis, patch testing, and allergen avoidance","volume":"112","author":"Burkemper","year":"2015","journal-title":"Mo Med"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1067\/mai.2000.104937","article-title":"The diagnostic evaluation, treatment, and prevention of allergic contact dermatitis in the new millennium","volume":"105","author":"Belsito","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Suppl","key":"10.1016\/B978-0-323-95061-9.00017-5_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2015.02.009","article-title":"Contact dermatitis: a practice parameter\u2014update 2015","volume":"3","author":"Fonacier","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib13","unstructured":"Johnson MLT. Skin conditions and related need for medical care among persons 1\u201374 years, United States, 1971\u20131974. Series 11, data from the National Health Survey November, No. 212, DHEW Pub No. (PHS) 79-1660. U.S. Department of Health, Education, and Welfare, Public Health Service, National Center for Health, Hyattsville, MD; 1978."},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2133.2001.04082.x","article-title":"Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry","volume":"144","author":"Faergemann","year":"2001","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.01.001","article-title":"Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies","volume":"31","author":"Dessinioti","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib16","series-title":"Clinical dermatology: a color guide to diagnosis and therapy","article-title":"Psoriasis and other papulosquamous diseases","author":"Habif","year":"2016"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib17","series-title":"Clinical dermatology: a color guide to diagnosis and therapy","article-title":"Eczema and hand dermatitis","author":"Habif","year":"2016"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000018220","article-title":"Nummular eczema: an addition of senile xerosis and unique cutaneous reactivities to environmental aeroallergens","volume":"199","author":"Aoyama","year":"1999","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib19","first-page":"301","article-title":"Vulvar dermatoses: a review and update","volume":"112","author":"Simonetta","year":"2015","journal-title":"Mo Med"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib20","series-title":"StatPearls [Internet]","article-title":"Lichen simplex chronicus","author":"Charifa","year":"2020"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2019.1708856","article-title":"A systematic review of evidence based treatments for lichen simplex chronicus","volume":"32","author":"Juarez","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/01443615.2017.1329283","article-title":"Skin diseases of the vulva: eczematous diseases and contact urticaria","volume":"38","author":"Sand","year":"2018","journal-title":"J Obstet Gynaecol"},{"issue":"21","key":"10.1016\/B978-0-323-95061-9.00017-5_bib25","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/B978-0-323-95061-9.00017-5_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/ajh.22139","article-title":"Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Wilcox","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2009.11.692","article-title":"Infectious agents in cutaneous T-cell lymphoma","volume":"64","author":"Mirvish","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5017","key":"10.1016\/B978-0-323-95061-9.00017-5_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1126\/science.1857968","article-title":"Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides","volume":"253","author":"Hall","year":"1991","journal-title":"Science"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-3083.2004.00937.x","article-title":"Clinicopathological spectrum of mycosis fungoides","volume":"18","author":"Kazakov","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib30","series-title":"Clinical dermatology: a color guide to diagnosis and therapy","article-title":"Premalignant and malignant nonmelanoma skin tumors","author":"Habif","year":"2016"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib31","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199506293322608","article-title":"Chronic urticaria","volume":"332","author":"Greaves","year":"1995","journal-title":"NEJM"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Pt 2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib33","first-page":"521","article-title":"The diagnosis and management of urticaria: a practice parameter part I: acute urticaria\/angioedema part II: chronic urticaria\/angioedema. Joint Task Force on Practice Parameters","volume":"85","author":"Joint Task Force on Practice Parameters","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2249.2008.03693.x","article-title":"An approach to the patient with urticaria","volume":"153","author":"Deacock","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2222.2009.03256.x","article-title":"Pathogenesis of chronic urticaria","volume":"39","author":"Kaplan","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2005.06646.x","article-title":"Thyroid autoimmunity in chronic urticaria","volume":"153","author":"O\u2019Donnell","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib37","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib38","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jaci.2004.02.049","article-title":"Chronic urticaria: pathogenesis and treatment","volume":"114","author":"Kaplan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1081-1206(10)62099-6","article-title":"Sensitivity to nonsteroidal anti-inflammatory drugs","volume":"89","author":"Namazy","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00017-5_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0091-6749(89)90180-2","article-title":"Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients","volume":"84","author":"Leznoff","year":"1989","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2230.2003.01228.x","article-title":"Aspirin sensitivity and urticaria","volume":"28","author":"Grattan","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2340\/00015555-1109","article-title":"High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria","volume":"91","author":"Staubach","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1067\/mai.2000.105706","article-title":"Chronic urticaria","volume":"105","author":"Greaves","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib45","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.1999.02767.x","article-title":"The extent and nature of disability in different urticarial conditions","volume":"140","author":"Poon","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/archderm.1987.01660280064024","article-title":"Cholinergic urticaria. A clinical and histologic study","volume":"123","author":"Hirschmann","year":"1987","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2230.2007.02376.x","article-title":"Acquired cold urticaria: clinical picture and update on diagnosis and treatment","volume":"32","author":"Siebenhaar","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00017-5_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archderm.134.1.106","article-title":"Clinical predictive factors of severity in cold urticaria","volume":"134","author":"Mathelier-Fusade","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/archderm.1971.04000230083015","article-title":"Aquagenic urticaria","volume":"104","author":"Chalamidas","year":"1971","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/B978-0-323-95061-9.00017-5_bib50","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/j.1398-9995.2009.02177.x","article-title":"The definition and diagnostic testing of physical and cholinergic urticarias\u2014EAACI\/GA2LEN\/EDF\/UNEV consensus panel recommendations","volume":"64","author":"Magerl","year":"2009","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/B978-0-323-95061-9.00017-5_bib51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11882-017-0722-1","article-title":"Review of physical urticarias and testing methods","volume":"17","author":"S\u00e1nchez-Borges","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0738-081X(99)00062-0","article-title":"Urticarial vasculitis","volume":"17","author":"Black","year":"1999","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/CRIAI:23:2:201","article-title":"Urticarial vasculitis","volume":"23","author":"Venzor","year":"2002","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib54","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaip.2018.05.006","article-title":"Mimickers of urticaria: urticarial vasculitis and autoinflammatory diseases","volume":"6","author":"Davis","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib56","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib58","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0889-8588(05)70295-1","article-title":"Mastocytosis and the skin","volume":"14","author":"Soter","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib60","first-page":"7","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"Ayala-Font\u00e1nez","year":"2016","journal-title":"Psoriasis (Auckland, N.Z.)"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2008.07.045","article-title":"Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology","volume":"61","author":"Drago","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib62","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1747.2002.00200.x","article-title":"Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6","volume":"119","author":"Watanabe","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00017-5_bib63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-4632.2009.04062.x","article-title":"Lichen planus","volume":"48","author":"Lehman","year":"2009","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11596-007-0632-x","article-title":"The expression of TNF-alpha and ICAM-1 in lesions of lichen planus and its implication","volume":"27","author":"Chen","year":"2007","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib65","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1155\/2007\/19854","article-title":"Th1\/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus","volume":"2007","author":"Rhodus","year":"2007","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib66","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00130832-200410000-00013","article-title":"The immunological and clinical spectrum of delayed drug-induced exanthems","volume":"4","author":"Lerch","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib68","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib69","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib70","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2011.10.015","article-title":"Drug-induced epidermal necrolysis: important new piece to end the puzzle","volume":"128","author":"Roujeau","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00017-5_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic","volume":"85","author":"Wetter","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/B978-0-323-95061-9.00017-5_bib73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00017-5_bib74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib75","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0190-9622(85)70207-1","article-title":"Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases","volume":"13","author":"Ruiz-Maldonado","year":"1985","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 1","key":"10.1016\/B978-0-323-95061-9.00017-5_bib76","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis (Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib77","series-title":"Clinical dermatology: a color guide to diagnosis and therapy","article-title":"Exanthems and drug eruptions","author":"Habif","year":"2016"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib78","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/B978-0-323-95061-9.00017-5_bib79","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2013.03.024","article-title":"Characteristics of liver injury in drug-induced systemic hypersensitivity reactions","volume":"69","author":"Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/B978-0-323-95061-9.00017-5_bib81","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib82","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib83","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00130832-200208000-00006","article-title":"Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells","volume":"2","author":"Britschgi","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib85","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0002-9440(10)64486-0","article-title":"Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation","volume":"161","author":"Schmid","year":"2002","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00017-5_bib86","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis. Analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/B978-0-323-95061-9.00017-5_bib87","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib88","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archderm.1984.01650400102024","article-title":"Fixed drug eruption. A brief review","volume":"120","author":"Korkij","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/B978-0-323-95061-9.00017-5_bib89","series-title":"Dermatology in public health environments","first-page":"519","article-title":"Adverse drug reactions","author":"Criado","year":"2017"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib90","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/B978-0-323-95061-9.00017-5_bib91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.autrev.2011.04.003","article-title":"Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature","volume":"10","author":"Sagi","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib92","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jama.284.3.350","article-title":"Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations","volume":"284","author":"Yancey","year":"2000","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00017-5_bib93","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/B978-0-323-95061-9.00017-5_bib94","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/B978-0-323-95061-9.00017-5_bib95","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1582-4934.2007.00033.x","article-title":"Immunopathology and molecular diagnosis of autoimmune bullous diseases","volume":"11","author":"Mihai","year":"2007","journal-title":"J Cell Mol Med"},{"issue":"10","key":"10.1016\/B978-0-323-95061-9.00017-5_bib96","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.autrev.2015.06.005","article-title":"Oral mucosal manifestations of autoimmune skin diseases","volume":"14","author":"Mustafa","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/B978-0-323-95061-9.00017-5_bib97","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"}],"container-title":["Allergic and Immunologic Diseases"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323950619000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:08:54Z","timestamp":1757056134000},"score":24.122768,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323950619000175"}},"issued":{"date-parts":[[2022]]},"ISBN":["9780323950619"],"references-count":97,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-95061-9.00017-5","published":{"date-parts":[[2022]]}},{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:23:27Z","timestamp":1772781807257,"version":"3.50.1"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>An allergic or type I hypersensitivity reaction involves a misdirected immune overreaction to innocuous environmental and dietary antigens called allergens. The genetic predisposition to allergic disease, referred to as atopy, can be expressed as a variety of manifestations\u2014e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, allergic asthma, anaphylaxis. Globally, allergic diseases are one the most common types of chronic conditions. Several factors have been identified to contribute to the pathogenesis and progression of the disease, leading to distinctively variable clinical symptoms. The factors which can attenuate or exacerbate allergic reactions can range from genetic heterozygosity, the prominence of various comorbid infections, and other factors such as pollution, climate, and interactions with other organisms and organism-derived products, and the surrounding environment. As a result, the effective prevention and control of allergies remains to be one of the most prominent public health problems. Therefore, to contextualize the current knowledge about allergic reactions, this review paper attempts to synthesize different aspects of an allergic response to describe its significance in the global health scheme. Specifically, the review shall characterize the biomolecular mechanisms of the pathophysiology of the disease based on underlying disease theories and current findings on ecologic interactions and describe prevention and control strategies being utilized. An integrated perspective that considers the underlying genetic, immunologic, and ecologic aspects of the disease would enable the development of more effective and targeted diagnostic tools and therapeutic strategies for the management and control of allergic diseases.<\/jats:p>","DOI":"10.3389\/falgy.2023.1215616","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T13:09:03Z","timestamp":1691068143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Immunologic, genetic, and ecological interplay of factors involved in allergic diseases"],"prefix":"10.3389","volume":"4","author":[{"given":"Robbi Miguel G.","family":"Falcon","sequence":"first","affiliation":[]},{"given":"Salvador Eugenio C.","family":"Caoili","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2466-12-13","article-title":"Particular characteristics of allergic symptoms in tropical environments: follow up to 24 months in the FRAAT birth cohort study","volume":"12","author":"Acevedo","year":"2012","journal-title":"BMC Pulm Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00239-019-09895-3","article-title":"Allergy in an evolutionary framework","volume":"88","author":"Daschner","year":"2020","journal-title":"J Mol Evol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/9781118738818.ch60","article-title":"Allergies in birds","volume":"1","author":"Nett-Mettler","year":"2014","journal-title":"Veterinary Allergy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijbiomac.2018.01.178","article-title":"Antiparasitic effects induced by polyclonal IgY antibodies anti-phospholipase A2 from bothrops pauloensis venom","volume":"112","author":"Borges","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16384","DOI":"10.1074\/jbc.M801321200","article-title":"Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure","volume":"283","author":"Taylor","year":"2008","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.4049\/jimmunol.1200188","article-title":"Extensive diversification of IgD-, IgY-, and truncated IgY(\u0394Fc)-encoding genes in the red-eared turtle (trachemys scripta elegans)","volume":"189","author":"Li","year":"2012","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/apa.13515","article-title":"The allergic march comprises the coexistence of related patterns of allergic disease not just the progressive development of one disease.","volume":"105","author":"Goks\u00f6r","year":"2016","journal-title":"Acta Paediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9899.1000202","article-title":"The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma","volume":"5","author":"Zheng","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12016-021-08899-6","article-title":"Immunology of aging: the birth of inflammaging","volume":"64","author":"Fulop","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acel.13352","article-title":"Short and dysfunctional telomeres protect from allergen-induced airway inflammation","volume":"20","author":"Pi\u00f1eiro-Hermida","year":"2021","journal-title":"Aging Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1399-3038.2012.01294.x","article-title":"Oxidative stress in the airways of children with asthma and allergic rhinitis","volume":"23","author":"Celik","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-020-1295-4","article-title":"Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy","volume":"21","author":"McGeachie","year":"2020","journal-title":"Respir Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.anai.2021.04.021","article-title":"The atopic march and its prevention","volume":"127","author":"Jimenez","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-019-3561-1","article-title":"Preventive and therapeutic effects of trichinella spiralis adult extracts on allergic inflammation in an experimental asthma mouse model","volume":"12","author":"Sun","year":"2019","journal-title":"Parasit Vectors"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s00436-020-06884-0\/Published","article-title":"Immunomodulatory effect of different extracts from angiostrongylus cantonensis on airway inflammation in an allergic asthma model","volume":"119","author":"Pascoal","year":"2020","journal-title":"Parasitol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/emph\/eoab006","article-title":"Between a hygiene rock and a hygienic hard place","volume":"9","author":"Parker","year":"2021","journal-title":"Evol Med Public Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/falgy.2022.1051368","article-title":"The hygiene hypothesis for allergy\u2014conception and evolution","volume":"3","author":"Perkin","year":"2022","journal-title":"Front Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00388","article-title":"The hygiene hypothesis, old friends, and new genes","volume":"10","author":"Frew","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2249.2010.04133.x","article-title":"99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: darwinian medicine and the \u201chygiene\u201d or \u201cold friends\u201d hypothesis","volume":"160","author":"Rook","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/emph\/eot004","article-title":"Microbial \u201cold friends\u201d, immunoregulation and stress resilience","volume":"2013","author":"Rook","year":"2013","journal-title":"Evol Med Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.immuni.2020.10.002","article-title":"Regulatory T cell-derived TGF-\u03b21 controls multiple checkpoints governing allergy and autoimmunity","volume":"53","author":"Turner","year":"2020","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.4049\/jimmunol.1202354","article-title":"Regulatory T cells migrate to airways via CCR4 and attenuate the severity of airway allergic inflammation","volume":"190","author":"Faustino","year":"2013","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/mi.2016.47","article-title":"CD4\u2009+\u2009Th2 Cells are directly regulated by IL-10 during allergic airway inflammation","volume":"10","author":"Coomes","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0040314","article-title":"Adoptive transfer of induced-treg cells effectively attenuates murine airway allergic inflammation","volume":"7","author":"Xu","year":"2012","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.micinf.2017.11.001","article-title":"Evolution of the hygiene hypothesis into biota alteration theory: what are the paradigms and where are the clinical applications?","volume":"20","author":"Villeneuve","year":"2018","journal-title":"Microbes Infect"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1086\/417049","article-title":"The functon of allergy: immunological defense against toxins","volume":"66","author":"Profet","year":"1991","journal-title":"Q Rev Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.immuni.2013.10.006","article-title":"Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity","volume":"39","author":"Palm","year":"2013","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12948-022-00170-3","article-title":"Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience","volume":"20","author":"Glaeser","year":"2022","journal-title":"Clin Mol Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.waojou.2020.100496","article-title":"Safety and tolerability of venom immunotherapy: evaluation of 581 rush- and ultra-rush induction protocols (safety of rush and ultra-rush venom immunotherapy)","volume":"14","author":"Stock","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5114\/ada.2017.67082","article-title":"Safety and efficacy of venom immunotherapy: a real life study","volume":"34","author":"Ko\u0142aczek","year":"2017","journal-title":"Postepy Dermatol Alergol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coi.2015.07.001","article-title":"Testing the \u201ctoxin hypothesis of allergy\u201d: mast cells, IgE, and innate and acquired immune responses to venoms","volume":"36","author":"Tsai","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/all.14570","article-title":"The evolution of IgE-mediated type I hypersensitivity and its immunological value","volume":"76","author":"Pritchard","year":"2022","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1152\/ajplung","article-title":"Surfactant protein D increases phagocytosis and aggregation of pollen-allergen starch granules","volume":"288","author":"Erpenbeck","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.rmed.2003.12.018","article-title":"Factors affecting SP-A-mediated phagocytosis in human monocytic cell lines","volume":"98","author":"Ding","year":"2004","journal-title":"Respir Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaci.2012.11.037","article-title":"Ige cross-linking critically impairs human monocyte function by blocking phagocytosis","volume":"131","author":"Pyle","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/mi.2013.34","article-title":"Dysregulation of alveolar macrophages unleashes dendritic cell-mediated mechanisms of allergic airway inflammation","volume":"7","author":"Lauzon-Joset","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jlb.60.5.573","article-title":"C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation","volume":"60","author":"Lukacs","year":"1996","journal-title":"J Leukoc Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1152\/ajplung.00103.2017.-Histamine","article-title":"Synergistic mucus secretion by histamine and IL-4 through TMEM16A in airway epithelium","volume":"313","author":"Kang","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2018.00206","article-title":"Macrophage phagocytosis and allergen avoidance in children with asthma","volume":"6","author":"Kulkarni","year":"2018","journal-title":"Front Pediatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.4049\/jimmunol.2200294","article-title":"Androgens alleviate allergic airway inflammation by suppressing cytokine production in Th2 cells","volume":"209","author":"Ejima","year":"2022","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.4049\/jimmunol.1800293","article-title":"Testosterone decreases house dust Mite\u2013induced type 2 and IL-17A\u2013mediated airway inflammation","volume":"201","author":"Fuseini","year":"2018","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-018-0892-y","article-title":"Leptin receptor gene polymorphisms and sex modify the association between Acetaminophen use and asthma among young adults: results from two observational studies","volume":"19","author":"Ziyab","year":"2018","journal-title":"Respir Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20181117","article-title":"Estrogen ameliorates allergic airway inflammation by regulating activation of NLRP3 in mice","volume":"39","author":"Cheng","year":"2019","journal-title":"Biosci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000331437","article-title":"Estrogen stimulates Th2 cytokine production and regulates the compartmentalisation of eosinophils during allergen challenge in a mouse model of asthma","volume":"158","author":"Cai","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1258\/acb.2011.011052","article-title":"Immunoglobulin E deficiency: a forgotten clue pointing to possible immunodeficiency?","volume":"48","author":"Unsworth","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10184160","article-title":"Spectrum of disease manifestations in patients with selective immunoglobulin E deficiency","volume":"10","author":"Picado","year":"2021","journal-title":"J Clin Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nri.2016.75","article-title":"Immunity by equilibrium","volume":"16","author":"Eberl","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI5155","article-title":"Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation","volume":"103","author":"Hansen","year":"1999","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1021\/acs.jafc.0c07167","article-title":"L -Arabinose attenuates gliadin-induced food allergy via regulation of Th1\/Th2 balance and upregulation of regulatory T cells in mice","volume":"69","author":"Wang","year":"2021","journal-title":"J Agric Food Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5152\/tao.2015.1187","article-title":"The relationship between Th1\/Th2 balance and 1\u03b1, 25-dihydroxyvitamin D3 in patients with allergic rhinitis","volume":"53","author":"Keles","year":"2016","journal-title":"Turk Arch Otolaryngol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/all.14261","article-title":"Protein S protects against allergic bronchial asthma by modulating Th1\/Th2 balance","volume":"75","author":"Asayama","year":"2020","journal-title":"Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1038\/s41598-023-32507-6","article-title":"Experimental observation of the effect of immunotherapy on CD4+ T cells and Th1\/Th2 cytokines in mice with allergic rhinitis","volume":"13","author":"Zhu","year":"2023","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jmii.2015.01.004","article-title":"Toll-like receptor 1 N248S polymorphism affects T helper 1 cytokine production and is associated with serum immunoglobulin E levels in Taiwanese allergic patients.","volume":"50","author":"Yang","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"B54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1046\/j.1440-1592.1998.00105.x","article-title":"HLA Class II association with type I allergy to house dust mite and Japanese cedar pollen in Japanese subjects","volume":"47","author":"Sadanaga","year":"1998","journal-title":"Allergol Int"},{"key":"B55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.18502\/ijaai.v19i4.4111","article-title":"Association between two single nucleotide polymorphisms of thymic stromal lymphopoietin (TSLP) gene and asthma in Iranian population","volume":"19","author":"Ranjbar","year":"2020","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2340\/00015555-2578","article-title":"The value of flg null mutations in predicting treatment response in atopic dermatitis: an observational study in Finnish patients","volume":"97","author":"Luukkonen","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.alit.2016.02.007","article-title":"Exhaled nitric oxide and inducible nitric oxide synthase gene polymorphism in Japanese asthmatics","volume":"65","author":"Sato","year":"2016","journal-title":"Allergol Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/ng.3985","article-title":"Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology","volume":"49","author":"Ferreira","year":"2017","journal-title":"Nat Genet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/annrheumdis-2022-222460","article-title":"Multi-Trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component","volume":"81","author":"Shirai","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41588-018-0121-0","article-title":"A genome-wide cross-trait analysis from UK biobank highlights the shared genetic architecture of asthma and allergic diseases","volume":"50","author":"Zhu","year":"2018","journal-title":"Nat Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1183\/13993003.02298-2016","article-title":"Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma","volume":"50","author":"Hekking","year":"2017","journal-title":"Eur Respir J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jaci.2017.06.037","article-title":"Pathway discovery using transcriptomic profiles in adult-onset severe asthma","volume":"141","author":"Hekking","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28973-7","article-title":"Nasal airway transcriptome-wide association study of asthma reveals genetically driven mucus pathobiology","volume":"13","author":"Sajuthi","year":"2022","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-83185-1","article-title":"Epigenome-wide association study on asthma and chronic obstructive pulmonary disease overlap reveals aberrant DNA methylations related to clinical phenotypes","volume":"11","author":"Chen","year":"2021","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.143058","article-title":"Targeted DNA methylation profiling reveals epigenetic signatures in peanut allergy","volume":"6","author":"Zhou","year":"2021","journal-title":"JCI Insight"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30781-3","article-title":"Integrative epigenomic analysis in differentiated human primary bronchial epithelial cells exposed to cigarette smoke","volume":"8","author":"Glass","year":"2018","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67502-8","article-title":"Inhalation exposure to cigarette smoke and inflammatory agents induces epigenetic changes in the lung","volume":"10","author":"Seiler","year":"2020","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-50873-y","article-title":"Airway epithelial cell isolation techniques affect DNA methylation profiles with consequences for analysis of asthma related perturbations to DNA methylation","volume":"9","author":"Clifford","year":"2019","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1004059","article-title":"DNA Methylation changes separate allergic patients from healthy controls and may reflect altered CD4+ T-cell population structure","volume":"10","author":"Nestor","year":"2014","journal-title":"PLoS Genet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-35088-6","article-title":"Nasal DNA methylation at three CpG sites predicts childhood allergic disease","volume":"13","author":"van Breugel","year":"2022","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12103193","article-title":"Decreased histone acetylation levels at Th1 and regulatory loci after induction of food allergy","volume":"12","author":"Alhamwe","year":"2020","journal-title":"Nutrients"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02414","article-title":"Epigenetic regulation via altered histone acetylation results in suppression of mast cell function and mast cell-mediated food allergic responses","volume":"9","author":"Krajewski","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41390-018-0031-y","article-title":"Early-life antibiotics attenuate regulatory T cell generation and increase the severity of murine house dust mite-induced asthma","volume":"84","author":"Adami","year":"2018","journal-title":"Pediatr Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/pr.2017.20","article-title":"Prenatal exposure to bisphenol A and risk of allergic diseases in early life","volume":"81","author":"Zhou","year":"2017","journal-title":"Pediatr Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/7573103","article-title":"Bisphenol A exacerbates allergic inflammation in an ovalbumin-induced mouse model of allergic rhinitis","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81231-6","article-title":"Bisphenol A, S or F mother\u2019s dermal impregnation impairs offspring immune responses in a dose and sex-specific manner in mice","volume":"11","author":"Malais\u00e9","year":"2021","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-94673-9","article-title":"Diesel exhaust particles increase nasal symptoms and IL-17A in house dust mite-induced allergic mice","volume":"11","author":"Jung","year":"2021","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s10653-019-00481-6","article-title":"Haze facilitates sensitization to house dust mites in children","volume":"42","author":"Ye","year":"2020","journal-title":"Environ Geochem Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-018-0235-6","article-title":"Dual exposure to smoking and household air pollution is associated with an increased risk of severe asthma in adults in Brazil","volume":"8","author":"Fernandes","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"B80","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10453-021-09726-3","article-title":"\u2018Pollen potency\u2019: the relationship between atmospheric pollen counts and allergen exposure","volume":"37","author":"Tegart","year":"2021","journal-title":"Aerobiologia (Bologna)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s13280","article-title":"Grassland allergenicity increases with urbanisation and plant invasions","volume":"51","author":"Bernard-Verdier","year":"2022","journal-title":"Ambio"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.envres.2019.108953","article-title":"Influence of residential land cover on childhood allergic and respiratory symptoms and diseases: evidence from 9 European cohorts","volume":"183","author":"Parmes","year":"2020","journal-title":"Environ Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijheh.2007.09.003","article-title":"Domestic allergens and endotoxin in three hospitals offering in-patient rehabilitation for allergic diseases in the alpine mountain climate of bavaria\u2014the AURA study","volume":"212","author":"Eberlein","year":"2009","journal-title":"Int J Hyg Environ Health"},{"key":"B84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/iid3.316","article-title":"Seasonality of allergic diseases: real-world evidence from a nationwide population-based study","volume":"8","author":"Lee","year":"2020","journal-title":"Immun Inflamm Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/all.12364","article-title":"Allergic airway diseases in a tropical urban environment are driven by dominant mono-specific sensitization against house dust mites","volume":"69","author":"Andiappan","year":"2014","journal-title":"Allergy"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1073\/pnas.2013284118\/-\/DCSupplemental","article-title":"Anthropogenic climate change is worsening north American pollen seasons","volume":"118","author":"Anderegg","year":"2021","journal-title":"Environ Sci (Ruse)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/S2542-5196(19)30015-4","article-title":"Temperature-related changes in airborne allergenic pollen abundance and seasonality across the northern hemisphere: a retrospective data analysis","volume":"3","author":"Ziska","year":"2019","journal-title":"Lancet Planet Health"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025091","article-title":"Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria A pilot study","volume":"100","author":"Su","year":"2021","journal-title":"Medicine (United States)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26266-z","article-title":"Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance","volume":"12","author":"De Filippis","year":"2021","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.1029125","article-title":"Suspected gut barrier disruptors and development of food allergy: adjuvant effects and early immune responses","volume":"3","author":"Dr\u00f8nen","year":"2022","journal-title":"Front Allergy"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/nu9111234","article-title":"Asthmatic patients with vitamin D deficiency have decreased exacerbations after vitamin replacement","volume":"9","author":"Solidoro","year":"2017","journal-title":"Nutrients"},{"key":"B93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.anai.2021.02.027","article-title":"Vitamin D and iron status in children with food allergy","volume":"127","author":"Nowak","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-015-0054-y","article-title":"A practical approach to vitamin and mineral supplementation in food allergic children","volume":"5","author":"Meyer","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07398-8","article-title":"Multiple nutritional and gut microbial factors associated with allergic rhinitis: the hitachi health study","volume":"12","author":"Sahoyama","year":"2022","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nm.3444","article-title":"Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis","volume":"20","author":"Trompette","year":"2014","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1166389","article-title":"Microbial characterization of the nasal cavity in patients with allergic rhinitis and non-allergic rhinitis","volume":"13","author":"Che","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jmii.2022.01.006","article-title":"Nasopharyngeal microbial profiles associated with the risk of airway allergies in early childhood","volume":"55","author":"Tsai","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.630345","article-title":"The relationship between lower respiratory tract microbiome and allergic respiratory tract diseases in children","volume":"12","author":"Cui","year":"2021","journal-title":"Front Microbiol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55712-8","article-title":"Allergic inflammation alters the lung microbiome and hinders synergistic co-infection with H1N1 influenza virus and Streptococcus pneumoniae in C57BL\/6 mice","volume":"9","author":"LeMessurier","year":"2019","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30259-2","article-title":"Chitin promotes antigen-specific Th2 cell-mediated murine asthma through induction of IL-33-mediated IL-1\u03b2 production by DCs","volume":"8","author":"Arae","year":"2018","journal-title":"Sci Rep"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41385-018-0028-1","article-title":"The common \u03b3-chain cytokine IL-7 promotes immunopathogenesis during fungal asthma","volume":"11","author":"Reeder","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55836-x","article-title":"Schizophyllum commune induces IL-17-mediated neutrophilic airway inflammation in OVA-induced asthma model mice","volume":"9","author":"Hanashiro","year":"2019","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85277-4","article-title":"Interleukin-33 and thymic stromal lymphopoietin, but not interleukin-25, are crucial for development of airway eosinophilia induced by chitin","volume":"11","author":"Arae","year":"2021","journal-title":"Sci Rep"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2020.105664","article-title":"Indoor microbiome, environmental characteristics and asthma among junior high school students in johor bahru, Malaysia","volume":"138","author":"Fu","year":"2020","journal-title":"Environ Int"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2022.107137","article-title":"Indoor microbiome, air pollutants and asthma, rhinitis and eczema in preschool children\u2014a repeated cross-sectional study","volume":"161","author":"Sun","year":"2022","journal-title":"Environ Int"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-021-01091-0","article-title":"Indoor bacterial, fungal and viral species and functional genes in urban and rural schools in shanxi province, China\u2013association with asthma, rhinitis and rhinoconjunctivitis in high school students","volume":"9","author":"Fu","year":"2021","journal-title":"Microbiome"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-019-0695-5","article-title":"Concurrent measurement of microbiome and allergens in the air of bedrooms of allergy disease patients in the Chicago area","volume":"7","author":"Richardson","year":"2019","journal-title":"Microbiome"},{"key":"B109","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.rmed.2016.12.010","article-title":"Characteristics associated with clinical severity and inflammatory phenotype of naturally occurring virus-induced exacerbations of asthma in adults","volume":"123","author":"Bjerregaard","year":"2017","journal-title":"Respir Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-022-01949-1","article-title":"Profiles and predictive value of cytokines in children with human metapneumovirus pneumonia","volume":"19","author":"Xiang","year":"2022","journal-title":"Virol J"},{"key":"B111","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1172\/JCI119516","article-title":"Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen","volume":"100","author":"Schwarze","year":"1997","journal-title":"J Clin Invest"},{"key":"B112","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1465-9921-11-14","article-title":"Early-life viral infection and allergen exposure interact to induce an asthmatic phenotype in mice","volume":"11","author":"Siegle","year":"2010","journal-title":"Respir Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0091-6749(98)70012-0","article-title":"Influenza A virus infection increases IgE production and airway responsiveness in aerosolized antigen-exposed mice","volume":"102","author":"Suzuki","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5415\/apallergy.2017.7.4.206","article-title":"Comparison of nasal cytokine profiles of human metapneumovirus and respiratory syncytial virus","volume":"7","author":"Park","year":"2017","journal-title":"Asia Pac Allergy"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1183\/09031936.02.00019902","article-title":"RSV Bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life","volume":"20","author":"Schauer","year":"2002","journal-title":"Eur Respir J"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008204","article-title":"The molecular epidemiology of respiratory viruses associated with asthma attacks","volume":"96","author":"Saraya","year":"2017","journal-title":"Medicine (United States)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1183\/09031936.02.00254302","article-title":"Respiratory viral infections as promoters of allergic sensitization and asthma in animal models","volume":"19","author":"Schwarze","year":"2002","journal-title":"Eur Respir J"},{"key":"B118","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jaci.2017.07.025","article-title":"Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness","volume":"140","author":"Edwards","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jaci.2020.03.037","article-title":"Human TH1 and TH2 cells targeting rhinovirus and allergen coordinately promote allergic asthma","volume":"146","author":"Muehling","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000334150","article-title":"Strategies to prevent or reduce allergic disease","volume":"59","author":"Prescott","year":"2011","journal-title":"Ann Nutr Metab"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2005.03.043","article-title":"Primary prevention of asthma and allergy","volume":"116","author":"Arshad","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/0161-5890(80)90095-4","article-title":"Ige and IgG antibodies compete for antigenic determinants of Parietaria officinalis allergen","volume":"17","author":"Giallongo","year":"1980","journal-title":"Mol Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/0161-5890(96)84613-X","article-title":"The affinity of allergen specific IgE and the competition between IgE and IgG for the allergen amb a V sensitive individuals","volume":"33","author":"Kim","year":"1996","journal-title":"Mol Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jaci.2017.09.054","article-title":"An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor Fc\u03b3RIIb","volume":"142","author":"Zha","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1186\/2045-7022-4-20","article-title":"Allergen sensitization linked to climate and age, not to intermittent-persistent rhinitis in a cross-sectional cohort study in the (sub)tropics","volume":"4","author":"Larenas-Linnemann","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.alit.2017.05.004","article-title":"Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model","volume":"66","author":"Ujino","year":"2017","journal-title":"Allergol Int"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1039\/c3ay41698d","article-title":"Simultaneous determination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate, loratadine, meclizine and buclizine in pharmaceutical formulations, human serum and pharmacokinetics application","volume":"6","author":"Sher","year":"2014","journal-title":"Anal Methods"},{"key":"B128","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1021\/jm9704311","article-title":"Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H 1-receptor antagonist","volume":"41","author":"Pagliara","year":"1998","journal-title":"J Med Chem"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00783","article-title":"Primary non-adherence to antihistamines\u2014conclusions from E-prescription pilot data in Poland","volume":"11","author":"Kardas","year":"2020","journal-title":"Front Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/14622416.10.3.375","article-title":"Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria","volume":"10","author":"Palikhe","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B131","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000487482","article-title":"\u201cReal-life\u201d efficacy and safety aspects of 4-year omalizumab treatment for asthma","volume":"27","author":"Al-Ahmad","year":"2018","journal-title":"Med Princ Pract"},{"key":"B132","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","article-title":"Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab","volume":"292","author":"Davies","year":"2017","journal-title":"J Biol Chem"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.596908","article-title":"An omalizumab biobetter antibody with improved stability and efficacy for the treatment of allergic diseases","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging fc\u03b3 receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J Clin Invest"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-29664-4","article-title":"Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI157765","article-title":"IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms","volume":"132","author":"Kuo","year":"2022","journal-title":"J Clin Invest"},{"key":"B139","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4161\/mabs.28394","article-title":"A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma","volume":"6","author":"Cohen","year":"2014","journal-title":"MAbs"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-04207-w","article-title":"Discovery of an agonistic siglec-6 antibody that inhibits and reduces human mast cells","volume":"5","author":"Schanin","year":"2022","journal-title":"Commun Biol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2332\/allergolint.54.143","article-title":"A double-blind trial of Lactobacillus paracasei strain KW3110 administration for immunomodulation in patients with pollen allergy","volume":"54","author":"Fujiwara","year":"2005","journal-title":"Allergol Int"},{"key":"B142","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1164\/rccm.200806-951OC","article-title":"Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice","volume":"179","author":"Karimi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imu.2019.100280","article-title":"Package of anti-allergic probiotic Lactobacillus by focusing on the regulatory role of immunosuppressive motifs in allergy","volume":"18","author":"Mazhary","year":"2020","journal-title":"Inform Med Unlocked"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-78404-0","article-title":"Dietary prebiotics promote intestinal Prevotella in association with a low-responding phenotype in a murine oxazolone-induced model of atopic dermatitis","volume":"10","author":"Laigaard","year":"2020","journal-title":"Sci Rep"},{"key":"B145","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/gut.51.1.51","article-title":"Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning?","volume":"51","author":"Kirjavainen","year":"2002","journal-title":"Gut"},{"key":"B146","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/JAA.S334752","article-title":"The multiomics analyses of gut Microbiota, urine metabolome and plasma proteome revealed significant changes in allergy featured with indole derivatives of tryptophan","volume":"15","author":"Zhen","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B147","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/all.12608","article-title":"Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge","volume":"70","author":"Scadding","year":"2015","journal-title":"Allergy"},{"key":"B148","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2332\/allergolint.47.213","article-title":"Long-term house dust immunotherapy improves pulmonary functions in children and adolescents with bronchial asthma","volume":"47","author":"Matsumoto","year":"1998","journal-title":"Allergol Int"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0063233","article-title":"Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity","volume":"8","author":"Ru\u00ebff","year":"2013","journal-title":"PLoS One"},{"key":"B150","doi-asserted-by":"publisher","first-page":"505S","DOI":"10.1177\/0145561319882593","article-title":"Comparison of sublingual immunotherapy in patients with allergic rhinitis sensitive to house dust mites in Korea","volume":"100","author":"Jung","year":"2021","journal-title":"Ear Nose Throat J"},{"key":"B151","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1248\/bpb.b18-00710","article-title":"Comparison of the allergenic potency of house dust extract and house dust mite allergen extract for subcutaneous allergen immunotherapy","volume":"42","author":"Du","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-021-00588-5","article-title":"Comparison of weight per volume and protein nitrogen units in non-standardized allergen extracts: implications for prescribing subcutaneous immunotherapy","volume":"17","author":"Dua","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.alit.2020.09.011","article-title":"Effect of oral immunotherapy in children with milk allergy: the ORIMA study","volume":"70","author":"Maeda","year":"2021","journal-title":"Allergol Int"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.611474","article-title":"Bovine holo-Beta-lactoglobulin cross-protects against pollen allergies in an innate manner in BALB\/c mice: potential model for the farm effect","volume":"12","author":"Afify","year":"2021","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"00639","DOI":"10.1183\/23120541.00639-2022","article-title":"Adding a biologic to allergen immunotherapy increases treatment efficacy","volume":"9","author":"Bo\u017cek","year":"2023","journal-title":"ERJ Open Res"},{"key":"B156","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/evan.21931","article-title":"Leveling with tinbergen: four levels simplified to causes and consequences","volume":"31","author":"Bergman","year":"2022","journal-title":"Evol Anthropol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"106","DOI":"10.15586\/aei.v49i5.438","article-title":"Prevalence of symptoms, severity and diagnosis of asthma in adolescents in the province of salamanca, Spain: global asthma network (GAN) phase I","volume":"49","author":"Mar\u00edn-Cassinello","year":"2021","journal-title":". Allergol Immunopathol (Madr)"}],"container-title":["Frontiers in Allergy"],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1215616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T13:09:07Z","timestamp":1691068147000},"score":24.113544,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1215616\/full"}},"issued":{"date-parts":[[2023,8,3]]},"references-count":157,"alternative-id":["10.3389\/falgy.2023.1215616"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2023.1215616","ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"published":{"date-parts":[[2023,8,3]]},"article-number":"1215616"},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T05:01:29Z","timestamp":1648616489196},"reference-count":0,"publisher":"Sift Desk","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAAID"],"DOI":"10.25177\/jaaid.1.1.1","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T05:15:07Z","timestamp":1508303707000},"source":"Crossref","is-referenced-by-count":0,"title":["Non-ionic Contrast Allergy Manifesting as Stevens Johnson Syndrome and Erythema Multiforme"],"prefix":"10.25177","volume":"1","member":"10815","published-online":{"date-parts":[[2017]]},"container-title":["Journal of Advances In Allergy &amp; Immunologic Diseases"],"original-title":["Non-ionic Contrast Allergy Manifesting as Stevens Johnson Syndrome and Erythema Multiforme"],"deposited":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T05:15:07Z","timestamp":1508303707000},"score":23.94088,"resource":{"primary":{"URL":"https:\/\/www.siftdesk.org\/article-details\/Non-ionic-Contrast-Allergy-Manifesting-as-Stevens-Johnson-Syndrome-and-Erythema-Multiforme\/27"}},"issued":{"date-parts":[[2017]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.25177\/jaaid.1.1.1","ISSN":["2575-6184"],"issn-type":[{"value":"2575-6184","type":"electronic"}],"published":{"date-parts":[[2017]]}}],"items-per-page":20,"query":{"start-index":0,"search-terms":"Immunologic+diseases.+Allergy"}}}